



Organisation of Pharmaceutical Producers of India

**Collaboration
Creation**

PUTTING THE
**COUNTRY
FIRST.**

TAKING THE
**COUNTRY
FAR.**

**Conservation
Communities**

2024



FOREWORD

Anil Matai

Director General, OPPI

To achieve progress, it is vital that success and service to the nation go hand in hand. When these factors are built on the strong foundation of sustainability, they create a powerful and lasting impact. This is the approach OPPI and its members have consistently upheld, as they strive tirelessly towards equitable healthcare for all. For the people, for the future – ***Bharat Ke Liye.***

As the pharma industry has evolved, so has the pressing need to find innovative solutions that are not just inclusive, but sustainable as well. Today, more than ever, we must work towards building a healthier planet, conserving resources like water and energy, managing chemical emissions, minimizing our environmental impact...while never ceasing in our efforts to produce life-saving medicines and treatments.

Last year has seen an exponential rise in treatment options, newer and improved medicines and increased focus on R&D, as witnessed by the multiple Centres of Excellence and Global Capabilities Centres being set up around the country. The year also witnessed many transformative CSR projects by our members – sustainability initiatives, awareness projects, educational initiatives and scholarships, flagship projects to benefit rural India and the environment, and schemes to improve access to medicines, etc, apart from employee volunteering programs. It has also been a time of collaborations and strategic partnerships.

This report enlists some of the noteworthy work done by 21 of our members. What stands out in it, is their continued commitment to community. And their determination to offer them sustainable solutions. Always.

INDEX

OPPI ORDINARY MEMBERS

01

Abbvie

CSR initiatives: Nurturing education, wellness and vision

07

AstraZeneca

Transforming Healthcare for millions of people

15

Bayer

Innovation and Access are key pillars

19

Boehringer Ingelheim

Transforming Health: Boehringer Ingelheim 2024 Milestones

27

Bristol Myers Squibb

Expanding boundaries of science and advancing patient health

31

Lilly

A medicine company turning science into healing to make lives better for people around the world

35

GSK

100 Years in India: A Legacy of Innovation, Impact, and Transforming Healthcare

41

Johnson & Johnson

Leading where medicine is going

47

Merck

Sparking Discovery, Elevating Humanity – Committed to Advancing Lives Together

51

MSD

Bringing Hope to Humanity

71

Pfizer

Committed to Building a Healthier India

55

Novartis

Unleashing the power of people to reimagine medicine in India for the world

75

Roche

A healthier future. It's what drives us to innovate.

63

Novo Nordisk

Driving Change in the Lives of People Living with Serious Chronic Diseases

83

Sanofi

In India...for India and the world

67

Otsuka

Quality. Trust. Wellbeing.

89

Servier

Bringing Hope to Cancer Patients in India

OPPI AFFILIATE MEMBERS

93

ACG

Collaborating to create a Better Healthier World

105

Parexel

Expediting excellence; accelerating access

99

Indegene

Enabling healthcare organizations to be future-ready

111

Pharmapoint

Supply that's Safe, Secure & Sustainable

CSR initiatives: nurturing education, wellness and vision

Standing tall in the pharma world, AbbVie's steadfast mission has always been to deliver innovative medicines and solutions that address multiple health issues and enhance people's lives. Making them a renowned name in several therapeutic areas, such as immunology, oncology, neuroscience, eyecare, and women's health, amongst others; treating 75+ conditions in over 70+ countries. Equally committed to their social responsibility, AbbVie has crafted transformative CSR programs with profound impact on fostering education, wellbeing, and vision among underprivileged communities.

AbbVie's vision: Empowering Communities, Enriching Lives.

AbbVie believes in the power of health, education, and wellness to transform lives. Through their ongoing CSR initiatives, the company is dedicated to making a meaningful impact in the communities they serve. From enhancing access to preventive health services and improving vision care, to supporting education and promoting overall well-being, their efforts are centred around empowering individuals to live healthier, happier lives.

AbbVie collaborated with Sight Savers with a shared goal to improve eye health of the rural population including the truckers, poor and the underserved in the project geography through primary eye health services.

The company's collaboration with Christel House India demonstrates their dedication to empowering children from under-resourced communities to realize their potential and transform their futures.

Further, collaborating with Mobility India embodies their entrepreneurial spirit to innovate and improve the lives of people with disabilities, their families, older people, disadvantaged groups, and other people in need.

AbbVie joined hands with The Akshay Patra Foundation to ensure that no child in India is deprived of education due to hunger, demonstrating the value they put on child welfare, societal growth, well-being and the cultivation of human capital.

The Tata Memorial Centre is renowned for not only delivering high quality cancer care to patients from all sections of the society, but also has a strong focus on cancer prevention, education and conducting quality research. This shared vision has resulted in a beautiful collaboration between AbbVie and Tata Memorial Centre.

The company is excited to share the strides they've made in creating lasting change across key focus areas: preventive health, education, vision care, and wellness. By focusing on these pillars, the company aims to address some of society's most pressing challenges, ensuring that every person regardless of background or circumstance has the opportunity to thrive.

Sight Savers India

Since 1996, Sight Savers has been serving to combat avoidable blindness, restore sight and work for the rights and needs of people with disabilities (PWDs).

Project Goals with Support from AbbVie:

A year-long National Truckers Eye Health Project (Raahi) in 10 cities (Jamshedpur, Hyderabad, Mangalore, Udaipur, Jodhpur, Dewas, Bokaro, Nagaon, Goa and Guntur) touching lives of more than 19,000 beneficiaries.

Major Activities:

- Quality and quantity of vision centres
- Free spectacle dispensing in any Vision Centre
- Ready to Clip Spectacles
- Blood pressure check
- Cataract Referral
- Tele Calling to ensure usage of spectacles
- Increased demand and uptake of Eye Health Services
- Improved Awareness
- OTP Based Registration
- Digital Data Collection



Glaucoma Awareness Project:

A project to amplify awareness and engagement in glaucoma prevention, emphasizing early detection as well as treatment to prevent blindness and fostering community ownership in eye health initiatives through consultations and screenings.

Key Components of the Campaign:

- Awareness Initiatives through digital media campaigns and onground campaigns
- Community and public engagement through events, radio advertisements and celebrity endorsements.
- State-level Consultations organized across India in cities like Bhubaneswar, Bhopal, Bangalore, Lucknow, etc.



Christel House India

Christel House India, established in 2001, is part of a global network providing comprehensive support system the children from under-resourced communities need to thrive, both in school and beyond. The in-depth, whole-child approach integrates rigorous academic learning with nutrition and healthcare, life skills, socio-emotional support, college and career guidance, and scholarships to pay their college fees.

Project Goals with support from AbbVie

Education Sponsorship of students in Primary school - 93 students (70 students in kindergarten & 23 students in Grade 1) in Christel House India, Bangalore for 1 Year.



Mobility India

Mobility India (MI), established in 1994 in Bangalore as a Society, is a pioneer in the Disability, Rehabilitation, and Development sector. MI has championed Physical Rehabilitation & Assistive Technology (PR&AT) and Community-Based Inclusive Development programs.

Project Goals with support from AbbVie

Community-Based Inclusive Development in Tumkur, Chikkanayakanahalli, Turuvekere, and Sira Taluks of Tumkur District, Karnataka for a year.

- Promote the health and well-being of 250 children with disabilities or at risk for disabilities by providing them with nutritional supplements.
- Equal access to safe and accessible portable drinking water by installing 40 water purifiers at Anganwadi
- Promotion of inclusive education and child rights by Training of PDO's in inclusion of children with disabilities and learning disabilities in the 40 Grama Sabhas
- Health Care, and Assistive Technology Services for older people by training 100 community health officers in assistive care for the elderly - 4 taluks



The Akshaya Patra Foundation

The Akshaya Patra Foundation, established in 2000 and headquartered in Bengaluru, India serves wholesome, highly nutritious, and palatable food every school day to over 2 million children from 22,367 schools across 15 states and 2 Union Territories of India for the past 22 years.

Project Goals with support from AbbVie

One year sponsorship of School Meals for 6666 children in 90+ Government schools in Hubli, Karnataka.



Tata Memorial Centre

Tata Memorial Centre (TMC) is a National Comprehensive Cancer Centre and a Grant-in-Aid institute under the administration of Department of Atomic Energy, Government of India, providing highly subsidized cancer care to the patients with many treated free of charge.

Project Goals with support from AbbVie

Donation of Thoracic Vascular Instrument sets for lung and oesophageal cancer patients at Tata Memorial Hospital, Mumbai benefitting approximately 300 patients per year.

Transforming Healthcare for millions of people

AstraZeneca's illustrious journey of 45 years in India since 1979, is a demonstration of its purpose to push the boundaries of science and transforming healthcare and sustainably impacting people, society and the planet.

Embracing the "Science Can We Can" mindset, the organization is driven by shared values that prioritize service to people, society, and the planet. As one of the most diverse and fastest-growing countries in the Asia Area, AstraZeneca India plays a pivotal role in their global ambition.

A #Fabulous45 years journey in the country is marked by their strong focus on transforming healthcare by harnessing science to bring medicines that address unmet medical needs FASTER and to build innovative access strategies in close collaboration with the ecosystem for equitable healthcare with respect to treatment, diagnosis, expanded access to novel therapies and making healthcare systems more resilient.



Diverse & Unique Footprint

The company has grown exponentially in the country over years and today their unique footprint comprising over 4500 employees is their biggest strength. Today, the company has two entities in the country a) AstraZeneca Pharma India Limited, a publicly listed company with commercial organization focused on bringing innovative medicines faster to India, a manufacturing facility and a SMM team conducting global clinical trials in India across all therapy areas they are present in-Oncology, Biopharmaceuticals and Vaccines & Immune Therapies and Rare Disease and b) AstraZeneca India Pharma Ltd, that comprises of their GCC, R&D and GBS business spread across Chennai and Bengaluru. This business plays a key role in innovation and transformation projects, enabling and empowering AstraZeneca's core business processes – from discovery, development, production, launches to supply all the way through the value chain.

Last year, the company announced an additional investment to expand this Global Innovation and Technology Centre in India, creating around 1,300 highly skilled roles by 2025. The company is proud to say that India is the nerve centre of technology and innovation for AstraZeneca, leading their digital agenda worldwide.

Growth Through Innovation

AstraZeneca thrives on pushing the boundaries of science to deliver life changing medicines. The company achieved robust growth and successfully implemented their specialist-focused strategy well supported by their unique talent base. It marked notable regulatory approvals and submissions, or approvals for their medicines or life-cycle management indications, and advancements in their pipeline. In the past two years they secured more than 12 regulatory approvals that are helping address patient unmet needs in the country.

AstraZeneca's **India Innovation Hub under A Catalyst Network** is a dynamic network of solutions addressing present and future healthcare challenges by connecting AstraZeneca with collaborators from outside traditional pharma. This collective approach is vital for improving patient outcomes, driving innovation, and speeding up the delivery of new treatments. The company strive's to create healthier societies, collaborating with their partners to tackle major health challenges.



AstraZeneca accelerated its collaborations in the country to enhance access-both with governments and partners. Partnership with state government of Karnataka and Goa to detect Lung Cancer early. The company is collaborating to deploy Artificial Intelligence (AI) based Lung Cancer screening technology developed by Qure.ai that will screen a patient for 29 lung diseases in one chest X-ray. They launched 'Partnership for Health System Sustainability and Resilience' (PHSSR) India report through a collaboration with an independent research initiative, based on a framework from the London School of Economics, that aims to improve global health by building knowledge through strong research, providing evidence-based policy recommendations, and diverse partnerships to implement health policies. Through PHSSR, their goal is to ensure future health systems are resilient and can meet the needs of people effectively.



PHSSR

In Oncology: the company is leading a revolution to redefine cancer care, with the ambition to eliminate cancer as a cause of death. Their approach involves understanding the complexities of cancer to develop life-changing treatments and increase the potential for cure.

In Biopharmaceuticals (Cardiovascular, Renal & Metabolism, Respiratory & Immunology, Vaccine & Immune Therapy): the company's ambition here is to intervene earlier to protect vital organs, slow or reverse disease progression, and achieve remission for these often degenerative, debilitating, and life-threatening conditions so many more people can live better, healthier lives. They are furthering this ambition to deliver the next generation of therapeutics in their pipeline, focusing on specialists, science, and innovation, while improving access of their existing portfolio in specialist disease areas -Heart Failure, Diabetes, Asthma, RSV, COPD.

In Rare Disease: RD patients face many unique clinical and practical challenges in pursuing equitable access to healthcare. The company focuses on overcoming barriers to access, supplying medicines for rare diseases through their patient support and expanded access programmes.

They're helping create healthier societies, collaborating with their partners to tackle major health challenges; working to identify and remove access barriers to give people everywhere the chance to be as healthy as possible.

Unique and Diverse talent is the company's strength

They are building a strong performing and values driven organisation that can partner in building winning strategies to excel as a specialist focused organisation in India, so they can make a sustainable impact to people, society and the planet.

Employees are their assets and they're empowering their people to reach their full potential in a dynamic, inclusive and high performing working environment. The company is building a 'Psychological Safe' culture where teams can speak up and truly belong. One of their corporate behaviours under their Value of 'We do the right thing' is 'I speak my mind and make it safe for others to do so'.

The company's Inclusion & Diversity (I&D) mission is to create an inclusive and equitable environment where people belong, AstraZeneca's Inclusion & Diversity strategy includes three strategic focus areas. They charted out a BOLD ambition in Jan 2023 to achieve 25% gender diversity by 2025 and focused on an exemplary approach by prioritizing women representation in senior roles. This demonstrated their Leadership commitment towards their I&D agenda. Targeted strategies coupled with strong engagement model to create a conducive environment for women to thrive at the workplace was crafted through their 'Diversity by Design' project which helped in achieving sharp increase (From 13% to 21%) in gender representation through the 'Buy, Build and Engage' strategy.

They are committed to fostering a culture of lifelong learning across the company. The company believes they need to continually strengthen and evolve their capabilities and instil the confidence to challenge convention and explore new possibilities, so that they can deliver life-changing medicines to patients now and in the future. By creating everyday development experiences, they provide boundaryless opportunities for employees to exercise their natural curiosity, empowering us all to develop new ideas and thrive in a fast-changing world.

AstraZeneca is proud to be recognised as a 'Great Place to Work' seven consecutive times and everything they do is underpinned by their dedication towards their people as they know what's possible with a talented and diverse team that believes in What Science Can Do.





Commitment to Society and Planet

Aligned with their value of 'doing the right thing,' they actively contribute to society and the planet. The correlation between a healthy planet and healthy people guides their ambitious actions to expand healthcare access while mitigating climate change impact.

Through the Ambition Zero Carbon strategy, the company is pursuing ambitious, science-based decarbonisation targets, accelerating progress towards net-zero, and managing the risks and opportunities presented by climate change. AZ Forest, their global reforestation and biodiversity initiative expanded, to plant and maintain 200 million trees by 2030, to restore over 100,000 hectares of land, benefiting communities, nature and health. Per design, the project will integrate reforestation principles with agroforestry, helping to preserve and restore local ecosystems and create sustainable opportunities for local communities. In line with their promise to plant 64 million trees across 22,670 hectares in Meghalaya, supporting biodiversity and soil conservation, as well as climate and catchment health co-benefits, happy to share that the program is progressing well with over 13.2 million saplings planted across EKH, WJH and WKH districts. They recently celebrated the 1ST Anniversary of launching AZ Forest in Meghalaya, and inaugurated the 'Besterley Earthtree Community Nursery' in Shillong. Welcomed HE Lindy C. British High Commissioner to India, Dr Andrew Fleming for the celebration.



With SankalpTaru Foundation, The company has 5,000 geo-tagged trees using Miyawaki and conventional plantation methods, including medicinal, fruit-bearing, and shade-giving trees, at the Open Air Jail in Devanahalli, Bangalore, Karnataka.



AZ Forest in Shillong

Their "Ganga Godavari Screening Programme" remains steadfast in identifying early cancer incidences among women in underserved communities, conducting over 10,000 women across 125+ camps in Delhi, Nasik, and Patna through specialised screening camps and community mobilisation.



The Young Health Programme, focused on educating young people about health choices, has reached over 95,000 youth through 43 community activities. In India, AstraZeneca strategically engages with local government bodies, and health offices in Karnataka, including the Ministry of Health and Family Welfare (MoHFW) and the Non-communicable Disease (NCD) Cell, as well as national health mission teams. This collaboration strengthens grassroots connections and enables the refinement of strategies for effective work in new communities.



In partnership with the IICARE Foundation, they introduced the 2,000 Improved Cookstove Project, marking a significant step towards fostering sustainable living and enhancing community health in rural areas across Maharashtra. This initiative aims to provide advanced, eco-friendly cookstoves to 2,000 households, significantly reducing the quantity of firewood fuel required per household and impacting over 8,000 beneficiaries.

Healthcare faces challenges all over the world. As the burden of disease grows and the population ages, the health needs of billions of people remain unmet. We need a fundamental shift from 'sick care' to health care, gearing our health systems to act earlier to prevent, detect and treat disease. This requires us to ensure patients can access the right treatment at the right time, provide holistic prevention focused on health education, literacy, and empowerment and finally, focus resources to prioritise interventions where 'acting early' is backed by strong evidence.

And while such challenges remain, they believe India is making significant strides in advancing its healthcare system. AstraZeneca's global ambition is to pioneers in science, lead in their disease areas and transform patient outcomes. By 2030, they will deliver 20 new medicines, industry-leading growth and be carbon negative.

AstraZeneca in India is building on its 45-year legacy of transforming healthcare and addressing unmet medical needs across therapeutic areas. Their purpose centers around transforming the future of healthcare by unlocking the power of what science can do.

They are committed to bringing next generation therapies to Indian patients faster and investing in healthcare capacity building, which includes ongoing efforts to support clinical research, innovation, leveraging technology and working inclusively and collaboratively, across the company and with others.

To transform healthcare for billions of people, they are focused on:

- science and innovation to deliver new medicines that address unmet medical need transforming outcomes for patients,
- increasing access to healthcare and making healthcare systems more resilient, while growing the success of their company
- contributing sustainably to people, society and the planet.

They are doing all this by using digital technologies, data and AI, and by working inclusively and collaboratively across the company and with others.





Innovation and Access are key pillars

Bayer is a global life sciences company with core competencies in health and nutrition. The company solves for two of the biggest challenges of our times - a growing and aging global population. It does this through significant contributions toward enhancing food security, increasing agricultural yield, providing innovative and accessible health care, and encouraging sustainable business practices.

Bayer has been present in India for over 127 years and it started bringing its pharmaceutical products into the country more than a century back. Since then, the company has grown from strength to strength. It has embedded itself in the Indian pharmaceutical industry through its strategic commitment to innovation, and focus on addressing critical healthcare needs in key therapy areas such as Cardiovascular, Diabetes, Kidney Health, Women's Healthcare, Oncology, and Ophthalmology. Across these areas, Bayer's global innovative brands hold leadership positions. The Bayer Pharmaceuticals division includes the Radiology business with a presence in devices and contrast agents.

WORKING TOWARDS ENSURING AS MANY PATIENTS BENEFIT FROM VITAL THERAPIES.

Bayer actively addresses the challenges of affordability and accessibility in the country through various strategies such as early introduction to innovative therapies, tiered pricing, patient support programs and strategic partnerships.

Early introduction of first-in-class therapies in areas of high disease burden, such as Kerendia (finerenone) and Verquvo (vericiguat) and novel drugs like Nubeqa (darolutamide), have been instrumental in propelling growth for the company. These innovative brands were launched in India within 15 to 18 months of their worldwide introductions.

Tiered pricing helps balance affordability with investment in innovation. Adopting this strategy, helps make life-saving medications available at reasonable costs. In India, Kerendia and Verquvo are priced much lower than many other developed countries.

When it comes to patient support programs, Bayer manages to help alleviate the financial burden of treatment and enhance adherence. For instance the Eylea support program has successfully assisted thousands of patients suffering from neovascular age-related macular degeneration and diabetic macular edema. Similarly, the Visanne Values You initiative addresses the needs of women with endometriosis, providing feasible alternatives like treatment adherence support and multilingual counseling.

The company's patient support programs like the Nu-Life and Nu-Life Circle of care programs for Nubequa, offer access to the drug at reduced costs and integrative oncology services, addressing the overall wellbeing of patients with prostate cancer by ensuring their emotional, physical & nutritional wellbeing through a virtual patient counselling service.

Bayer also leverages strategic partnerships to further improve healthcare delivery and patient care. In 2024, the global pharma company collaborated with Dr. Reddy's Laboratories and Sun Pharma to market and distribute second brands of vericiguat and finerenone, respectively. The collaboration is aimed at harnessing the two Indian pharma companies extensive marketing capabilities, to broaden patient access and improve health outcomes.

SOLIDIFYING IT'S INDIA COMMITMENT

In May 2024, Bayer acquired the remaining 25% stake in Bayer Zydus Pharma Private Limited (BZPPL), transitioning the joint venture with Zydus Lifesciences Limited to full ownership. This move will further facilitate the delivery of innovative health solutions leveraging established brands and local expertise.

Globally, Bayer is committed to research and development and India is a formidable part of that story. The Pharma R&D team established in Hyderabad is a part of a global team, contributing to Clinical Data Operations (CDO), Data Science & Artificial Intelligence (DS&AI), Oncology Statistics & Data Management (OSDM) & Clinical Imaging & Application. The team actively contributes across clinical data science & analytics for global phase II and III studies and also contributes to the area of SAS programming, medical coding, data management and data insight & generation. They also support AI/ML projects like Cell Painting (assays analysis through digitalization/ exploration) for RED ONC research group and Radiomics Radiology, Biomarkers and Clinical datasets. Teams from Bayer India also actively contribute globally to Trial Feasibility and Analytics (TFA) and GCIS - General Clinical Imaging Services (Radiology R&D).

As for participation in clinical trials from India, it is being increased to ensure that the country's population is better represented in innovation. This helps support faster introduction of innovative therapies in the country. Currently, the company has around 20 projects in India, across Phase II to IV studies including interventional and observational studies in various stages of completion and covering a range of potential therapeutic modalities and indications.

The Pharmacovigilance Regional center (PVRC) for Asia Pacific is currently located in India and many global pharmacovigilance activities including Global case processing, aggregate report writing, and IT support have been outsourced to TCS located in India.

COLLABORATION FOR GREATER GOOD

Bayer's global 100 million sustainability development goal is a key focus, with India playing a crucial role in achieving it. The commitment is to provide access to modern contraception for 100 million women in low- and middle-income countries by 2030.

In collaboration with the Family Planning Association of India (FPAI), Bayer aims to build sustainable models of care delivery for family planning for women in India. Bayer has also tied up with United Nations Family Planning Association (UNFPA), to support a program to educate the youth on family planning through a chatbot – Just Ask, and provides them options to consult with a health care provider. This collaboration extends to their engagement with Population Services International (PSI), emphasizing informed decision-making for young people regarding their sexual and reproductive health. Additionally, a collaboration with Ipas Development Foundation (IDF) will undertake training and outreach initiatives to increase access to contraception.

Going from strength to strength is Bayer's Preserve the Uterus (PTU) nationwide initiative, aimed at stemming unnecessary hysterectomies. It was launched in 2022 by the company in collaboration with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) and Integrated Health and Wellbeing (IHW) Council. Over 5000 healthcare practitioners have been trained through over 100 sessions to educate and address the concern of unwarranted hysterectomies among women in India, and they in turn cascade the sessions to post-graduate medical students.

2024 saw the Department of Health, Medical and Family Welfare - Government of Andhra Pradesh, join hands with Bayer to set up the country's first set of Preserve the Uterus (PTU) Centres of Excellence. Both centers are housed in Vizag, at King George Hospital and Victoria Hospital. The centers will offer training sessions to help upskill healthcare professionals, which will play a key role in reducing the rate of unnecessary hysterectomies in Andhra Pradesh and improve women's health in the state.



The Andhra Pradesh government with Bayer launched the country's first Preserve the Uterus Centre of Excellence in Vizag.

As part of the Oncology Sustainability Initiative, Bayer is working with the National Cancer Institute of India - All India Institute of Medical Sciences (NCI-AIIMS), to develop a sustainable model for delivering quality cancer care for the underserved rural population in and around Jhajjar (Haryana). With targeted screening among high-risk individuals, early disease detection and timely treatment, NCI-AIIMS has launched a screening program for prostate, head and neck/oral cancer with support from Bayer to

enhance cancer surveillance in India. An important feature of this collaboration is that patients who are identified through the screening initiative can make use of the Ayushman Bharat scheme of the Government of India to receive timely medical care. The five-year initiative will enable screening of approx. 12,000 patients in the geographical vicinity of NCR.



NCI-AIIMS cancer screening program in Jhajjar supported by Bayer

Bayer has also partnered with Karkinos Healthcare to scale up cancer screening in target communities in Mumbai and Puducherry. The collaboration combines Bayer's vision of "Health for All" and Karkinos' focus on early detection and aims to remedy cancer care disparities in target communities over the next two years. This project aims to screen 100,000 individuals, focusing on cancers including

oral, breast, cervix, colorectal, and prostate. The initiative ensures a care continuum by working closely and in partnership with the community and local institutions.

Bayer's Oncology Sustainability initiatives in India have been recognized in the Whitehouse Cancer Moonshot fact sheet which was issued in conjunction with the Indian Prime Minister, Mr. Modi's official visit to the US in June 2023.

Since 2022, Bayer's CSR initiative of establishing 28 'Phygital' telemedicine centres in rural and underserved areas has aligned with the government's goal of improving access to affordable healthcare. These telemedicine centres were strategically co-located in Primary Health Care Centres (PHCs) across 14 aspirational districts in eight states, bringing specialized healthcare services closer to remote communities. The centres provide teleconsultations in eight medical specialties, enabling communities to access expert medical advice without the need for long-distance travel. The day-to-day operations are managed by a General Nursing and Midwife along with a centre coordinator, while a General Physician offers consultations and prescriptions. The government also supports the initiative by providing essential medicines free of charge through PHC pharmacies. In addition to teleconsultations, the centres conduct training and awareness sessions on health, hygiene, and nutrition. Regular medical camps are held to educate the public on important health issues such as breast cancer, diabetes, dermatology, hypertension, pediatric care, gynecology, and pulmonology. Moving forward, Bayer plans to continue support to 20 telemedicine centres in Gujarat, Karnataka, Maharashtra, and Uttar Pradesh, further enhancing healthcare access for rural communities.

Going forward Bayer will continue to leverage partnerships of all types, to help advance its commitment of making innovative treatments accessible to as many patients as possible, thereby benefitting their health and quality of life.

Transforming Health: Boehringer Ingelheim 2024 Milestones

In 2024, Boehringer Ingelheim India continued its journey of innovation and excellence, achieving remarkable milestones across healthcare and animal health sectors. With a steadfast commitment to improving lives, the company introduced life saving therapies, strengthened its portfolio, and expanded access to critical treatments. Through partnerships, embracing digital transformation, and prioritizing sustainability, Boehringer Ingelheim India strengthened its position as a leader in driving impactful healthcare solutions and contributing to the well-being of millions across the nation.

Launches

Transforming chronic kidney care in India

In 2024, CDSCO approved Boehringer Ingelheim's innovator molecule Empagliflozin for treating chronic kidney disease (CKD), a condition impacting over 33 million adults. With existing indications in type 2 diabetes and heart failure, empagliflozin could help manage the risks of cardio-renal-metabolic conditions,



which are often interconnected. Cardio-renal-metabolic conditions affect over 1 billion people worldwide. The EMPA-KIDNEY phase III trial demonstrated its ability to reduce kidney disease progression risk by 28% and cardiovascular death by 14%. Boehringer engaged CKD patients as speakers in its launch meetings to amplify patient-centric care. This milestone reinforces Boehringer's leadership in cardio-renal-metabolic care.


Spesolimab: A new era in management of rare disease

CDSCO in India approved 'Spesolimab' as a treatment option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. Distinct from plaque psoriasis, GPP is a rare and potentially life-threatening neutrophilic skin disease, characterized by episodes of widespread eruptions of painful, sterile pustules. Given that it is so rare, recognizing the symptoms can be challenging and consequently lead to delays in diagnosis. Nationwide campaigns and collaborations with dermatologists marked the launch, highlighting Boehringer's dedication to addressing unmet needs in rare diseases.



Comprehensive parasite control for pets

Boehringer introduced a new product with an innovative molecule called afoxolaner for flea and tick protection in dogs, with a unique mode of action with rapid absorption. This launch expanded Boehringer's portfolio in India, offering broad-spectrum parasite protection for dogs. It is a soft, flavourful monthly chew that kills fleas before they can lay eggs, ticks and mites while eliminating gastro-intestinal worms and preventing heartworm disease, lungworm and eyeworm infections. With the safety and compliance of monthly dosing for coverage against internal and external parasites, it addresses India's growing pet population and reinforces the company's leadership in animal health.



Advancing in poultry health

Boehringer Ingelheim announced the launch of the latest advancement in Marek's disease vaccines in India. Marek's disease remains a significant challenge in Indian poultry, with outbreaks continuing despite widespread vaccination efforts.

The vaccine addresses this gap with a groundbreaking serotype-1 construct vaccine, offering an ideal balance of safety and efficacy against the most virulent strains. This next generation vaccine offers enhanced protection through an innovative controlled attenuation process, delivering the right balance between safety and efficacy. Further, this represents a breakthrough in vaccine engineering and is recommended for in-ovo vaccination of 18 to 19-day-old embryonated chicken eggs and one-day old chickens to protect against the virulent Marek's disease.



Pharmacovigilance

Shaping patient safety through launch of innovative comic book

During World Patient Safety Week, Boehringer partnered with PvPI and the Ministry of Health to launch a pharmacovigilance comic book, promoting safe medicine practices nationwide. Endorsed by dignitaries, this initiative will be translated into multiple languages, making patient safety advocacy accessible across India.



Strategic Collaborations

Revolutionizing stroke care: efforts towards improving pre hospitals stroke care in country.

Boehringer Ingelheim collaborated with RED.Health Ambulance, which largely covers private and corporate hospitals in 16 States in country with its patnered ambulance and EMRI Green Health Services, a GVK enterprise for 108 National Ambulance, which covers government hospitals in 14 states to improve stroke care in India. The MoU focuses on enhancing pre-hospital care within the critical 4.5-hour window, offering ESO/WSO endorsed EMT training and improves and enhance transfer protocols. The initiative aims to reduce stroke-related disability by strengthen pre-hospitals emergency care systems and improve pre-notification in hospitals for better stroke care outcomes.



(L to R - William Masih – Head-Angels Initiative India, Dr Tausif Thangalvadi – V.P. Operations – RED.Health Ambulance)



(L to R - Mr A Uma Maheshwar Rao, Dr Keshav Reddy G, Dr Raja Narsing Rao, Dr G V Ramana Rao, Mr. K Krishnam Raju, Mr. William Masih, Mr. Prabhat Sinha, Mr Rohan Gouri, Dr Javed Ashraf Syed)

Expanding pet care access: partnership with Vvaan life-sciences

Boehringer partnered with Vvaan Lifesciences to reach tier 2 markets, providing access to their innovative parasiticide portfolio to pets in these geographies. This strategic collaboration bridges gap in animal healthcare, ensuring quality veterinary care reaches underserved areas.



Strengthening partnership: collaboration with SIIC IIT Kanpur

Boehringer's grant to Manastik Technologies incubated at SIIC, IIT Kanpur supported the development of India's first tele-neurorehabilitation app for dementia care. This partnership highlights Boehringer's commitment to advancing socially impactful healthcare technologies.



Awards and Recognitions

Top Employer 2024

Boehringer Ingelheim India has been recognized as a 'Top Employer 2024' for the second consecutive year by the Top Employers Institute, an independent global authority that acknowledges excellence in people practices and culture. This accolade underscores the company's commitment to fostering a dynamic workplace focused on employee growth and inclusivity. The internal Boehringer Ingelheim University, launched in 2023, has been instrumental in this achievement, with over 60% of employees enhancing their professional development through this platform.



100 best companies for women in India

The company has also been recognized as one of the Best Companies for Women in India 2024, for the sixth time in a row, by Avtar Awards. This recognition underscores their strong commitment to advancing diversity, equity, and inclusion in India. It also reflects how the company's leadership initiatives are shaping an inclusive workplace culture for women, empowering them and fostering a supportive environment where they can thrive and achieve their career goals.



OPPI Marketing Excellence Award

Boehringer Ingelheim India received the Dr. H. R. Nanji Memorial OPPI Marketing Excellence Award for its outstanding marketing of Jardiance®. This award celebrates brilliance in pharmaceutical marketing, acknowledging exceptional creativity, strategic insight, and innovative campaigns that drive success.



ET Healthcare Awards 2024 - Excellence in CSR

The company's 'Stop Rabies' campaign was honored with the Excellence in CSR award at the ET Healthcare Awards 2024. This recognition underscores Boehringer Ingelheim India's commitment to impactful corporate social responsibility initiatives that address critical public health challenges.

DigiPharmaX - Outstanding achievement in pharma social media

At the 7th Edition of DigiPharmaX Awards 2024, Boehringer Ingelheim India was celebrated for its excellence in pharma social media, particularly for campaigns focused on stroke awareness. This accolade highlights the company's innovative approach to leveraging digital platforms for health education.





Top 30 Communications Teams by Reputation Today

Reputation Today recognized Boehringer Ingelheim India's communications team as one of the Top 30 Corporate Communications Teams for 2024. This honor reflects the team's effectiveness in strategic communication and its role in enhancing the company's reputation.

Angels initiative wins best stroke awareness initiative award at National Stroke Conclave 2024

The Angels Initiative has been honoured with the prestigious "Best Stroke Awareness Initiative" award at the National Stroke Conclave & Awards 2024, organized by the Voice of Healthcare (VOH). The National Stroke Conclave recognizes excellence in stroke care, bringing together key stakeholders from healthcare, policy, and industry to foster collaboration and showcase impactful initiatives.

The Angels Initiative was recognized for its exceptional collaboration with State Non-Communicable Disease (NCD) departments, significantly improving stroke care across India. Its innovative approach to public awareness, standardized protocols, and extensive training for healthcare professionals exemplifies the transformative power of collaborative efforts. Numerous hospitals have reached international standards of stroke care and gained global recognition.



Expanding boundaries of science and advancing patient health

Bristol Myers Squibb has been committed to India for more than 20 years and the company's continued investment highlights the ongoing importance of its role in its global business. In Bangalore, in partnership with Syngene International, employees in R&D work daily to support target identification, lead discovery and optimization and more. Through the pharmaceutical operations in Mumbai, BMS has been providing medicines to treat patients in oncology and hematology. The company's \$100 million investment in Hyderabad in 2023 has brought together over 2,000 employees across drug development, business Insights & technology, and global business-enabling functions to enhance their innovation capabilities for patients everywhere.

BMS Hyderabad: A transformative journey

Since it was set up in July 2023, the story of BMS in Hyderabad has been one of extraordinary growth and transformation. It has crystallised from a mere idea into a vibrant, fully functioning center with over 2,000 employees, and growing.

In the past year, the company's Drug Development team successfully established a comprehensive suite of capabilities spanning clinical development, clinical operations, regulatory, biometrics and safety, which are already delivering meaningful results. By co-locating these adjacent capabilities within India's talent and innovation-rich ecosystem, BMS is uniquely positioned to leverage synergies across the entire pharmaceutical value chain. This strategic alignment enables it to accelerate the company's mission of bringing more medicines to more patients, faster.

In Business Insights and Technology, the teams integrate the power of applications, platforms, Artificial Intelligence (AI), data and analytics to drive value and innovation for patients. They are not only advancing core capabilities but pioneering new ones, including, leading AI strategy and execution across both Analytical AI and Generative AI, and powering value through data, analytics, and actionable intelligence.

BMS is also expanding various business-enabling functions in Hyderabad to support global operations, to increase alignment and accelerate time to delivery.

These advancements are pivotal to the growth and success of BMS and are expected to significantly transform how it operates and delivers value.



Hyderabad Drug Development and Business Insights & Technology teams with global leaders

Patient Support Program in Oncology and Hematology

BMS endeavors to improve patient access and continues to support patients in India through its Patient Support Programs, enabling them to benefit from innovative medicines. The company believes that patients can only benefit from the medicines if they are able to access them. BMS presently offers patient support programs for treatments in Oncology (SAMBHAV) and Hematology (AARAMBH) in India. Over 30000 patients have benefitted from their oncology patient support program so far. BMS is committed to bringing more innovative medicines to more patients in India, faster.



India a part of global drug development for BMS

Samit Hirawat, EVP, Chief Medical Officer and Head of Development, visited India in 2024 and reinforced BMS' commitment to the country.

In an interview to The Hindu he said India is an integral part of BMS' global drug development operations. It is also growing in significance as a site for clinical trials, with a target to roughly double the number of clinical trials in about two years.

BMS is actively leveraging technology to improve the efficiency and speed of clinical trials, to help bring new products to market faster, he added. By using the best talent for innovation, BMS is focusing on building capabilities in India to support global drug development efforts.

'India is now part of global drug development for Bristol Myers Squibb'

Bristol Myers Squibb's executive vice-president says with India's growing significance as a site for clinical trials and innovations in drug development, it's time to mull allowing first-in-human clinical trials for drugs discovered outside of India

INTERVIEW

Samit Hirawat

N. Ravil Kumar
HYDERABAD

As the executive vice president, chief medical officer and head of development at Bristol Myers Squibb, Samit Hirawat oversees early-stage and late-stage product development across therapeutic areas for the biopharmaceutical major. In an exclusive chat with The Hindu, on a recent visit to Hyderabad, he discussed India's growing significance as a site for clinical trials, innovations in drug development, and how technology is poised to help bring new products to market faster.

BMS announced a \$100 million development centre in Hyderabad in 2023. Could you provide an overview of work in Hyderabad?

When I joined BMS about five and a half years ago, we didn't have a drug development presence in India. After COVID, as we were reinventing ourselves and our portfolio was growing at BMS, one of the ideologies I carried was we need to build talent pool not just in the New Jersey area or the United States, but how do we grow our presence and then utilise the talent wherever it is in the world? We did look at a few other cities, but homed in into



Hyderabad as talent exists here.

As opposed to many other companies that came, used Hyderabad and India to build capability and capacity for say ancillary activities, back office functions, we came in with the mentality that talent in India has grown quite a bit... got experience in the process of drug development.

So we brought in here not only IT capabilities, but also capabilities in development operations, conduct of clinical trials, regulatory capabilities, medical writing capabilities, biostatistics capabilities, data management capabilities, patient safety, pharmacovigilance capabilities. We have all of those functions contributing from here. India is the largest hub for us now in drug development operations, even bigger than all combined spaces that we have in the U.S.

What would that be in terms of staff focus on drug development?

Overall drug development [globally for BMS] is about 5,300 people, spread in

about 50 countries. Hyderabad houses close to 2,000 employees across functions. The drug development team is about 800-strong in Hyderabad and likely to grow 20-25% by next year. BMS in India is participating in more than 20 clinical trials across indications and we target to double that number in two years.

As Hyderabad emerges as a key centre, would it see more investment?

It's not in terms of money anymore, it's about using best talent for the best innovation. We only had seven clinical trials running in India 3-4 years ago... now have 23 clinical trials. Next year or by 2026, I want to have at least 50 clinical trials running in India. We used to run only oncology clinical trials in India before 2019. Now we are running immunology clinical trials, bringing in psychiatry clinical trials. We're bringing in haematological malignancies. And we are bringing drugs not yet registered in the U.S. So we are not doing life cycle management of drugs. We're actually doing true innovation.

On clinical trials, is there a need for review of regulations in India?

Regulations are there for safety of people and that appropriateness and transparency is there in terms of conduct of clinical trials. Indian regulations have

evolved. Drug development is getting faster, better with regulations. Should some things be changed? Probably yes. Right now India doesn't allow first-in-human trials for drug products discovered outside of India. Is that the right thing to do or not? And that is a conversation we need to have and continue to have with the regulators in India, that if you allow that in an appropriate setting at the right centres to do those first-in-human trials, I think it's the right time to do it because we've never seen innovation coming through at a speed that we are seeing today. I remember the stories of the past, but times have changed. More transparency has come through, people are more educated and we have better systems to monitor.

In what way is AI contributing to hasten clinical trials?

We looked deeper into the process of clinical trial and what we can do to do drug development at a faster pace. We found spaces where technology can help. For example, writing of a protocol, using more and more of Artificial Intelligence, Machine Learning... Let's say there are 17 sections to a protocol, maybe 12 can be automatically written because of prior knowledge. So we don't have to have human hands typing those and we can focus only 30% of our time in writing the rest of the sections. We can in-

crease productivity.

In terms of start-up activities, how we can use [technology for] clinical trial site selection and start-up packaging in terms of how to get the sites up and running in shortest period of time. In terms of enrolment, how do we identify patients? A lot of technology is going behind it.

Each of the components is using some sort of technology and that is shortening our period of drug development. Our aim is that in our pipeline, from first-in-human trial to [drug] approval, a median of about six-and-a-half years is what we want to get to and then continue to shorten that.

With use of emerging technologies, there are also reservations on their deployment...

One is the job perspective, that when AI and ML come in will my job go away? If I'm working 10 hours a day on a certain thing, if I can get machines to work for me for say, four hours of that because that's automated now I can still work 10 hours. So it's not the job going away, but becoming more productive using the machines.

The second element is quality and transparency. Am I cutting corners by using machines?

And I think that's all human dependent.

That's why we'll need to have the quality checks, QC and QA.

(For full interview visit <https://newsthehindu.com/2024/11/05/india-a-part-of-global-drug-development-for-bms/>)

Inspiring and enabling STEM futures

To foster the development and engagement of young minds in STEM education and careers, BMS partners with Janyaa Foundation that works with rural and underprivileged communities in Telangana state.

Experiential learning programs help children develop a strong STEM foundation which they can apply to their daily lives. Through these programs, BMS reached 22,000+ students, 200+ teachers and 55 schools in the 2024-25 academic year.

Via various training initiatives, BMS enabled:

- Janyaa Lab-in-a-box – A kit consisting of ~340 experiments developed in partnership with Stanford alumni, government teachers, and science/mathematics experts to help children understand science and math concepts through experiential learning
- Train the trainer – 80+ teachers trained through teacher learning materials and pedagogy
- Peer learning – Student-led sessions to promote student engagement and program ownership
- Eco-integrated Science and Math Clubs – Enabled student exploration of environmental and mathematical concepts and scientific curricula, promoting responsible community behaviour



BMS CEO Chris Boerner interacting with students from the Janyaa program in February 2024

A medicine company turning science into healing to make lives better for people around the world

Lilly started its operations in India more than 30 years ago and has a strong history of bringing innovative products in the areas of diabetes, oncology, immunology, and metabolic diseases to the country. Through their pharma operations, they are currently serving thousands of patients across the country.

Lilly currently operates in India through two business entities: Lilly Pharma (HQ: Gurgaon) and Lilly Capability Center India (HQ: Bengaluru). And recently, they also announced their plans to establish a new global capability centre (LCCI Hyderabad) in Hyderabad. With plans to hire 1,000 to 1,500 employees, LCCI Hyderabad is expected to open in mid-2025 and will drive innovation and technological advancement.

Lilly is a medicine company turning science into healing to make life better for people around the world. They've been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, their scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, Lilly is motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure their medicines are accessible and affordable. To learn more, visit <https://www.lilly.com/in/> and follow us on <https://www.linkedin.com/showcase/lilly-india/>.

Kadam Step Up – established by Lilly

Step Up school for underprivileged: Lilly initiated the Step Up program in 2014 with the goal of creating an ideal school for underprivileged children. The Step Up Centre enhances the educational status of children in migrant communities in Jharsa, Gurugram. Approximately 880 children have been educated at the Step Up Centre, 408 have been mainstreamed into regular schools through the Kadam program, 371 have received digital literacy training, and 101 Pre-School of the Future (PoF) children have been mainstreamed so far.

The school supports 220 children from underprivileged backgrounds through various programs.

- 1) **KADAM:** The Step Up Project (6 – 14 years). The project staff identifies drop-out and out-of-school children from the community, enrolls them into Kadam centres, where they are brought to their age-appropriate learning level using the Kadam methodology, and then mainstreamed into government schools.
- 2) **Pre-School of the Future (PoF):** Aims to provide education and care to children aged 3-6 years.
- 3) **Samarth Program:** Provides remedial educational support in the form of tuition classes after school hours.
- 4) **Digital Literacy Program:** A 3-month basic computer course to make children computer literate.
- 5) **Mid-day Meal Program:** To provide nutritional meals to the children at the centre, aiming to eradicate malnourishment.





Lilly Global Day of Service

Success is helping people heal – and Lilly understands that developing life-saving medicine is only the start of the conversation. Beyond medicines, Lilly has a longstanding history of social impact through partnering with local organizations to advance their efforts to promote healthy lives, healthy minds, and healthy communities. Lilly's Global Day of Service (GDOS) is one way thousands of employees connect to each other and their communities through volunteerism.

Last year, in September 2024, Lilly marked the 17th anniversary of GDOS, a day when Lilly employees around the world invest their time and talent through volunteerism, giving in ways that are meaningful to them and advance Lilly's purpose – to make life better for people around the world. The Lilly India team engaged in a range of educational and engagement activities with Step Up School, brought smiles to homeless elderly people in a shelter home, engaged with children at an orphanage, and participated in a forest plantation drive for a greener future.







100 Years in India: A Legacy of Innovation, Impact, and Transforming Healthcare

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. The company aims to positively impact the health of over 2.5 billion people in the next 10 years with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

GSK prioritizes innovation in vaccines and specialty medicines to prevent and treat disease. GSK focuses on science of the immune system and advanced technologies, investing in 4 core therapeutic areas (Infectious Diseases, HIV, Respiratory/Immunology and Oncology) to impact health at scale.

GSK is currently operating in over 75 countries and in India, the company has a legacy of 100 years.

70,200

GSK people

>75

countries worldwide

22,000

suppliers working directly with GSK

£6.2bn

R&D investment in 2023 - up 13% AER, 14% CER

37

manufacturing sites

4

global R&D centres in the US, UK, Belgium and Italy

About GSK in India

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK plc. With a history spanning nearly a century, GlaxoSmithKline Pharmaceuticals Limited has established a rich legacy in India.

Since 1924, GSK has been an integral part of the 'Make in India' story, advancing pharmaceutical research, development, and access to medicines. From foraying into the nutrition space in 1930 to a delivering a broad range of

general medicines that include anti-infectives and pain medicines, vitamins, dermatology products and vaccines for adults and children, GSK has addressed evolving healthcare needs of India for a century. Today, GSK's innovative solutions have helped set new benchmarks of excellence in the pharma industry with seven GSK brands featured in the top 100 Indian Pharmaceutical Market brands.

Disease Awareness Campaigns

Yeh Science Hain: Shingles 2.0 Campaign

"Yeh Science Hai": Amitabh Bachchan and Manoj Pahwa partner with GSK for new shingles awareness and prevention campaign

GSK's new campaign on Shingles awareness, featuring veteran actors Amitabh Bachchan and Manoj Pahwa, explaining the scientific link between chickenpox and Shingles. The campaign films use everyday conversations between two friends to talk about shingles and the increased susceptibility of shingles in people with diabetes. Shingles is caused by the re-activation of the virus that lies dormant in the nerves if a person has had chickenpox. People with a history of chickenpox who also have diabetes face a 40% higher risk of developing shingles. High blood sugar levels can weaken the immune system, and when that happens it can increase the risk of reactivation of the chickenpox virus and emergence of shingles.

GSK

Inactive Chickenpox virus can lead to Shingles years later.

Yeh Science Hai!

VACCINATION CAN HELP PREVENT SHINGLES

To know more about Shingles and its prevention consult your doctor or

Visit MyVaccinationHub.in

This advertisement features a black and white portrait of Amitabh Bachchan in a white hoodie, looking thoughtful with his hand to his chin. The text is overlaid on the left side. At the bottom, there is a banner with a woman holding her head in pain and a doctor in a white coat, with the text 'VACCINATION CAN HELP PREVENT SHINGLES' and a call to action to visit MyVaccinationHub.in.

GSK

Agar aapko Diabetes hai, toh Shingles bhi ho sakta hai.

Diabetes increases your risk of Shingles by 40%.

Yeh Science Hai!

VACCINATION CAN HELP PREVENT SHINGLES

To know more about Shingles and its prevention consult your doctor or

Visit MyVaccinationHub.in

This advertisement features a color portrait of Manoj Pahwa in a white kurta, holding a round, golden-brown fried snack. The text is overlaid on the left side. At the bottom, there is a banner with a woman holding her head in pain and a doctor in a white coat, with the text 'VACCINATION CAN HELP PREVENT SHINGLES' and a call to action to visit MyVaccinationHub.in.

Ab India Banega 7-Star

GSK's new campaign asks parents to support their children's future with 7 crucial vaccinations

GSK's new multichannel campaign 'Ab India Banega 7-Star' shows parents that the future of India is in their hands. It encourages them to secure their children's future with 7 essential vaccinations against 14 diseases, which include chickenpox, hepatitis A, hepatitis B, meningitis, measles, mumps, rubella, pneumonia, influenza, diphtheria, tetanus, pertussis, HiB infection, and polio.

The central creative focus of the campaign films is on the critical need for the 7 vaccinations. The two campaign films show professionals in different fields, such as a cricketer and a space-station mission director, pausing their important jobs to check if a child has received the 7 essential vaccinations. Current 'stars' of India giving a powerful message to parents of future 'stars' of India, is captured in the films. The films effectively convey the message that securing a child's future is more important than any other job and that this future rests on the 7-star protection offered by the 7 vaccinations.

GSK's commitment to India goes beyond their medicines to include the impact they make on our environment, sustainability and through Corporate Social Responsibility (CSR).



Environment

To get ahead of disease and to help ensure long-term business success, GSK has committed to a net zero, nature positive, healthier planet with ambitious goals set for 2030.

One of GSK's notable achievements has been the reduction of carbon emissions at its Nashik site, which reduced emissions by 310 tons of CO₂ equivalent by switching to a renewable biomass boiler and installing a 1 MW solar plant. The Nashik plant has also saved significant water by recycling treated water and using rainwater harvesting systems. These initiatives have reduced the site's freshwater consumption by 4,199 kilolitres, contributing to the company's goal to become water-neutral by 2030.

GSK's Women + Water Collaborative in India launched in October 2023 brings together companies from different sectors in India to leverage women's leadership for improving access to clean water and sanitation, ultimately supporting the health of local communities.





BusinessWorld Sustainability Awards 2023-24: GSK India has been ranked **#1 in the Pharma & Healthcare sector** in Businessworld India's Most Sustainable Companies 2023-24.

Corporate Social Responsibility

GSK has actively engaged in corporate social responsibility (CSR) initiatives through the years to address specified national objectives aligned with select UN Sustainable Development Goals (SDGs). These programmes focus on healthcare and education, the building blocks of a healthier and progressive nation. One such key initiative is supporting meritorious students from underserved backgrounds to pursue their education in Medicine. Additionally, they are working towards eliminating Lymphatic Filariasis, a debilitating disease which causes permanent disability. Till date, GSK has distributed nearly 3.96 billion albendazole tablets as part of its commitment to eradicate this disease in India.

Apart from these initiatives, GSK is contributing to digital learning initiatives and focuses on child nutrition under the National Urban Health Mission (NUHM) with a mission to uplift underserved communities. In the years to come, GSK will continue to build on this momentum to make a stronger and wider impact on our communities.



Leading where medicine is going

Johnson & Johnson (J&J) believes good health is the foundation of vibrant lives, thriving communities and forward progress. For over 135 years, they've been dedicated to keeping people all over the world well at every stage of life. Guided by their 'Our Credo', they strive to make healthcare more accessible and affordable, build healthier communities and bring a healthy mind, body and environment within reach for everyone, everywhere.

In 2024, Johnson & Johnson Innovative Medicine India (J&J IM) continued to bring this vision to life. Through groundbreaking innovations, impactful disease awareness campaigns and community initiatives, J&J IM India worked tirelessly to improve lives, foster resilience and create a lasting, meaningful impact across the country.

Shaping the future of medicine through cutting-edge innovations

They are inspired by patients and driven by science to create innovations that change and save lives.

By launching, DARZALEX Faspro® (Daratumumab and hyaluronidase), they bring a transformative approach to the multiple myeloma space. This advanced therapy cuts infusion time from 7 hours to just 7 minutes, while reducing infusion-related reactions by threefold compared to intravenous administration. As a ready-to-use immunotherapy with no dilution required, it provides enhanced convenience for patients. Their campaign "Back to Life in 5 mins" launched in Feb 2024 emphasizes time efficiency and patient comfort, impacting many patient lives.



DARZALEX Faspro® launch

Six months later, the company launched TECVAYLI® (Teclistamab), a first-in-class bispecific antibody for relapsed and refractory multiple myeloma. This innovative therapy demonstrated a 39% complete response rate and a 63% overall response rate. Like DARZALEX Faspro®, TECVAYLI® is also a ready-to-use solution requiring no dilution, further enhancing patient convenience. The "Tecvayli®: Power to Transform" campaign emphasized its transformative potential, with many patients already benefiting from this cutting-edge treatment.

Through these pioneering advancements, they reaffirm their commitment to delivering science-based solutions that empower patients and shape the future of medicine.



TECVAYLI® launch

Unveiling a Bold New Era with Updated Visual Identity

Johnson & Johnson marked a transformative moment in its journey by rebranding itself in India. This reflects the company's enduring commitment to innovation, compassion and advancing human health. It symbolizes a bold new era for Johnson & Johnson, uniting its people and purpose under a modernized look while staying true to its 135 years + legacy of care and trust.

Johnson & Johnson



Innovative Medicine



MedTech



Building Lung Cancer Awareness through an Impactful Campaign #IndiaDetectsToDefeat

India ranks 4th globally in lung cancer cases, accounting for 5.9% of all cancers and 8.1% of cancer-related deaths annually (WCRF). To address this, Johnson & Johnson Innovative Medicine India launched the #IndiaDetectsToDefeat campaign, focusing on raising awareness about Non-small Cell Lung Cancer (NSCLC) and Exon20i and emphasizing early detection to improve survival rates.

Partnering with Amar Chitra Katha (Tinkle), the cross-functional team created an engaging awareness booklet, "*The Power of Early Detection in the Fight Against Lung Cancer*", simplifying complex medical information into a vivid storytelling format. The booklet covers early signs, risk reduction, myths, and caregiver support.

Key achievements in four weeks:

- **External Engagement:** 7K+ printed booklets distributed to HCPs and government officials; 860+ e-booklet downloads; a press release featured in 15 media outlets, reaching 5.71K+ readers; industry stories and HCP articles published in top-tier publications such as Economic Times Pharma, Express Healthcare etc., achieving a combined reach of over 308M+. LinkedIn posts by leaders and employees further generated a reach of 15.6K+ viewers and 25.9K+ impressions

- **Internal Engagement:** 450 booklets were collected by employees from standee bookholders; the campaign was even launched at the India 2024 Town Hall; and mailers were shared via internal platforms, driving awareness



Celebrating Innovation and Collaboration

Since 2014, Science Day at Higi has been a cherished tradition, celebrating scientific achievements, overcoming challenges and fostering collaboration. In 2024, the event embraced the theme “DNA – Digital Transformation & Novel Analytics” and was graced by esteemed leaders, including Benedicte Lebreton, Koen Vanhoutte, Marjo Janssen, Pushkar Kulkarni and the Higi site leadership team.

The event featured insightful talks by Dr. Sumit Kumar Singh (IIT BHU) on ADCs for targeted therapy, Joydeep Ghosh and Rajit Nair (Deloitte) on digital transformation in life sciences and Pushkar Kulkarni (J&J) and his team, who shared updates on J&J IM business India. A poster session showcased the analytical teams’ innovative contributions to critical decisions, new modalities, and digitalization efforts, earning high praise from the leadership team for their dedication and teamwork.

Science Day at Higi continues to inspire and drive scientific excellence, embodying a commitment to innovation, collaboration and the future of healthcare.





Science Day at Higi

Driving Sustainability Through CSR

J&J's CSR activities for the year 2024-25 have been aligned with our Global Health Equity (GHE) priorities while continuing to address themes relevant to our region. Their key areas of focus this year are tuberculosis, mental health, vision, and global surgery, with a strong emphasis on the training of health workers, including Aanganwadi and ASHA workers.

Key Project Updates:

1. Training Health Workers and Disease Awareness

- They have launched three projects that began at the start of the financial year. One focuses on training health workers in Maharashtra and Andhra Pradesh, while the other two target raising awareness and providing treatment for both communicable and non-communicable diseases, including tuberculosis, in Aurangabad and NCR/Gurgaon

2. Mental Health and TB Support Initiatives

- Since October, their mental health awareness projects in the schools of Rajasthan, Madhya Pradesh, and their relief support efforts in Assam have been successfully initiated. They've also implemented additional projects focused on active TB case testing and awareness in the slums of Delhi and Hyderabad, as well as nutrition support for TB patients across eight states of Andhra Pradesh, Bihar, Haryana, Punjab, Maharashtra, Rajasthan, Telangana, and Uttar Pradesh

3. Global Surgery and Health Worker Capacity Building

- To prioritize global surgery, their West Bengal project will provide cleft lip and palate surgeries. In line with their goal to strengthen health worker capabilities, they will conduct capacity-building trainings for Auxiliary Nurse Midwife (ANMs), Accredited Social Health Activist (ASHA) workers, and Integrated Child Development Services (ICDS) workers in Mumbai, Palghar, and Satara districts of Maharashtra. These initiatives are scheduled to start in November

4. Disaster Relief

- In addition to their focus areas, they supported in providing relief packages for flood-affected families and individuals in Gujarat, Kerala, and Tripura in December

These projects are expected to impact the lives of over 0.5 billion individuals, either directly or indirectly, within this year alone.

Employee Volunteering:

1. **1372 employees** either participated or volunteered in community activities from Johnson & Johnson India (MedTech & Innovative Medicine).
2. Total volunteer hours of **2911** were spent either on organizing/hands on service.
3. **Twenty-two** NGOs guided and supported by experienced professionals boosting their community impact.
4. Employees voluntarily raised about **INR 4 lakhs** addressing immediate needs of vulnerable populations.

Awards received for CSR initiatives in 2024

1. FICCI Healthcare Excellence Awards 2024 for "Training and Skill Development Initiative of the Year"
2. Global CSR, Sustainability and ESG Awards 2024 for "Most Impactful Healthcare Support Initiative of the Year"

Sparking Discovery, Elevating Humanity – Committed to Advancing Lives Together

At Merck, science is the foundation of everything they do. It fuels their discoveries and drives the technologies they create. Every day, they make a positive impact on millions of lives. Their relentless curiosity and expert approach power their partnerships and bring innovative ideas to life.

In India, they accelerate access to innovative medicines, expand their portfolio, and leverage new assets to meet patient needs and adapt to changing dynamics. Focused on sustainable initiatives across their value chain, they embrace diversity and inclusive practices, aligning with their purpose: As One for Patients.

Merck Healthcare India
IN INDIA, FOR INDIA AND FOR THE WORLD

Advancing Science
1000+ team of Commercial & R&D

Accelerating Access
Govt. Partnerships and Digital health solutions

Maximize India Opportunity
Treat today's and future patients

Harness the talent footprint and technological advances

EXPERTISE

FERTILITY
Scientific leaders with complete portfolio

ONCOLOGY
Erbitux ranks 5th in targeted therapy*

CARDIOVASCULAR, METABOLISM & ENDOCRINOLOGY
Concor – No. 1 Beta blocker*

*Source – IQVIA, IPSOS report

Building inclusive organization through DEIB initiatives

At Merck, DEIB are essential for driving progress, fostering innovation and ensuring the sustainability of company. They pledge to their people, their partners, their patients and the industry to move the needle on their DEIB efforts, with robust aspirations in three focus areas Gender, Culture and ethnicity and Inclusion



Empowering future Women in Leadership

Merck partners with Unlurn to launch 'VOICE' program – a leadership program for women. Aims to awaken women to their innate leadership capacities, through an inside-out, awareness-based approach

Industry recognized award winning DEIB initiatives



CSR initiatives for larger impact

As a leading science and technology company, they take part in building the future and making life better for people all over the world. They focus their resources where they can achieve the most, engaging in three strategically important areas – Education, Health and Environment

Cancer care access



Children Education





**Grass root level activations...
1,20,000+ lives touched!**



Taking employee health strategy to the next level

The company launched BeHealthy, their global employee health strategy, to their workforce. It is designed to further strengthen the physical, mental, social, and workplace health of their employees.


BeHealthy



**Together we walked 100+mio steps
Highly engaged team**

Innovations driving sustainability goals across value chain

They aim to drive sustainability initiatives strongest impact through their entrepreneurial actions. Initiatives like reusable shipping material, innovative slim packs, state of the art warehouse facilities etc. strongly contribute to reducing their ecological footprint.



Ecological friendly logistics and reuse of shipping material



Innovative packaging reducing carbon footprints

Merck Vision



Bringing Hope to Humanity

MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, for more than 130 years, has brought hope to humanity through the development of important medicines and vaccines. In India, they focus on delivering innovations in oncology, vaccines, diabetes, and primary care. Additionally, they are also investing to advance health equity through partnerships; and expanding access to primary healthcare and supporting maternal health through their community initiatives.

Expanding and enabling access to health and education

Enabling access to health underpins every action MSD takes and every decision they make. They have partnered with the SMILE Foundation to improve access to primary healthcare across aspirational districts in India. Additionally, in partnership with The Apprentice Project (TAP), MSD is empowering under-served students with essential 21st-century skills using artificial intelligence.

TAP: Developing 21st century skills in children

Critical thinking, self-awareness, complex problem solving, self-confidence, and financial literacy are essential to thrive in the current world. MSD India in partnership with TAP has impacted over 10,000 students between age 11 – 17 from underprivileged communities with social and emotional learning skills. The program offered two formats - a) in-school or collaborative classroom learning and b) after-school self-paced learning via WhatsApp chatbot programs that students could choose from as a learning medium. Each student is unique and hence offering different learning methods offer the flexibility to the students to choose the best format for them. Students were offered personalized and individual courses on coding and science/electronics. Visual arts and performing arts through bot-driven interactions facilitated learning at their preferred pace.

The initiative was highly successful with students recording over 2,00,000 cumulative self-learning hours and creating 20,000+ projects on topics in line with the UN Sustainable Development Goals. Further, official partnerships with multiple State Government bodies, mentor teachers who were inducted as “Champions of Change” and a curriculum that aligned with most education boards ensured the program made a deeper impact.



Students showcasing projects at a showcase event

MSD Smile on Wheels: Expanding access, improving lives.

To ensure that primary healthcare services have better reach, MSD India has partnered with SMILE Foundation to improve access to primary healthcare services across aspirational districts through implementation of ‘mobile medical units.’ These mobile units have overcome traditional barriers to healthcare access such as geographical isolation, transportation issues, time constraints, and financial costs to provide primary healthcare services within the community enabling better health outcomes in the intervention populations.

The program has been implemented at 15 locations across 5 states including Uttar Pradesh, Bihar, Jharkhand, Assam, and Karnataka. The mobile medical units provide primary care services for common diseases, carry out screening activities and provide referral linkage to higher facilities. It also promotes preventive health in the community and provides point of care diagnostics. A key component of the program is to improve the health status of pregnant and lactating mothers to ensure safe motherhood. Additionally, it focuses on improving long-term health of the community, awareness sessions, home-visits, community mobilization and behaviour change initiatives are conducted regularly with the community. Over the years, more than 5000 OPD sessions have been conducted benefiting nearly 1.8 lakh people.



Project 1 at UP and Bihar - Launch at Lucknow



Project 2 at Jharkhand - Launch at Garwah



Project 3 at UP, Assam and Karnataka - Launch at Gorakhpur

Glimpses of the Mobile Medical Unit reaching out to the unreached in the Aspirational Districts





Unleashing the power of people to reimagine medicine in India for the world

Novartis is an innovative medicines company. Every day, they work to reimagine medicine to improve and extend people's lives. Their strategy is to deliver high value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. Their medicines reach more than 280 million people worldwide.

In India, Novartis has had a significant footprint since 1947, with two legal entities namely, Novartis Healthcare Private Limited, and Novartis India Limited. India is amongst a handful of countries in the world that has a broad Novartis presence including Pharma International (commercial division), Development (Drug Development division), Novartis Corporate Center (Global Capability Center) and Biomedical Research. Employing nearly 8,300 people, Novartis India has consistently been recognised as a Top Employer.

Every day, they work to reimagine medicine to improve and extend people's lives with their portfolio of innovative and established medicines in therapeutic areas including cardiovascular, oncology, immunology, eye care and neurosciences.

Strengthening heart health in India

Novartis has been at the forefront of transforming cardiovascular care in India, addressing critical unmet needs in heart health. As cardiovascular disease (CVD) remains a leading cause of morbidity and mortality in the country, Novartis is committed to creating meaningful impact through collaborations, awareness initiatives, and patient-centric programs.

I. Educating India to "Beat Bad Cholesterol"

Furthering their collaboration with The Times of India towards improving India's Heart Health, Novartis joined forces with the leading media house for their IP initiative "Beat Bad Cholesterol". This initiative is aimed at educating the nation on the critical and modifiable CV risk that uncontrolled LDL-C levels pose for one's heart. Through six editions of Times of Heart Health, disease awareness articles across 25 cities and disease awareness programs across hospitals, this initiative has reached over 500 million readers.

cardiovascular patient organization. This partnership originated from the APISx India convening, where the need for a unified patient voice in cardiovascular care was identified. Together, Novartis and HHIF: Co-created educational materials addressing patient and caregiver challenges. Further guided HHIF to establish a panel of esteemed cardiologists to guide patient-centric initiatives, advocated for localized patient charters with the Global Heart Hub, highlighting LDL-C as a critical modifiable risk factor. Novartis also played a pivotal role in facilitating HHIF's affiliation with the Asia Pacific CVD Alliance, signing an MoU with the Madhya Pradesh state government to integrate LDL-C screening alongside diabetes and hypertension in annual health check-ups across government hospitals.



NHM X HHIF MoU Signing



MoU signing at Madhya Pradesh NHM office

Through a tri-party collaboration with HHIF and The Times of India, Novartis expanded the reach of heart health education to over 80 hospitals, engaging patients, caregivers, and key stakeholders. A legacy of leadership in cardiovascular health Novartis' sustained efforts have created a ripple effect, raising awareness of LDL-C as a "silent thief of heart health" on global and local platforms. Through innovative initiatives, impactful multi-stakeholder collaborations, and a focus on patient-centric solutions, Novartis continues to strengthen the heart health ecosystem in India.

III. Driving scientific excellence in the cardiovascular space

India faces a significant cardiovascular health burden, accounting for one-fifth of global cardiovascular deaths. Despite 60% of Indians having high LDL-C levels, doctors believed patients were meeting target LDL goals post-events. Routine risk stratification during discharge was often neglected, leading to potential missed LDL targets. Insufficient doctor-patient communication left patients without accurate information, and lab reports provided non-individualized reference ranges, potentially misleading outcomes.



Recognized by OPPI as runner-up in the Medical Excellence category.

To address these issues, a two-pronged approach was implemented. A Real-world evidence (RWE) study involving 575 post-acute coronary syndrome (ACS) patients from 11 Indian centers revealed that 80% of patients had not achieved their LDL goals after one year. Individualized risk-based LDL-C goals were incorporated into hospital discharge protocols and lab reports, adopted by 90 hospitals in over 15 cities. Additionally, 20 laboratory chains in more than 600 cities integrated these risk-based LDL goals into their reports, impacting over 1,000,000 patients and aiming to improve outcomes continuously.

Impact of Novartis reimagining Cancer Care in India

Novartis is committed to reimagining the future of cancer care. At the heart of its mission lies a commitment to revolutionizing cancer care by addressing the pressing unmet needs of patients living with diverse types of cancer. With a broad oncology portfolio, they are dedicated to addressing these needs and developing innovative therapies that bring hope to patients and their loved ones.

I. Kyzific in India

The company focuses on combining the power of science and empathy to unravel the inner workings of cancer and develop innovative therapies that restore hope to those with cancer and their loved ones.

With over three decades of reimagining medicine and improving the heart health of people across the world, Novartis launched Asciminib (brand name: Kyzific) in April 2024, offering a beacon of hope to patients suffering from Chronic Myeloid Leukemia (CML).

This breakthrough treatment is designed for patients who have progressed on two prior therapies or carry the T315i mutation.

With its novel mechanism of action, Kyzific has the potential to deliver long-term, durable responses, setting a new standard in CML care. This drug enables Novartis to continue its legacy in this space after successfully transforming the treatment landscape with Gleevec and Tasigna.



The Kyzific team at the launch of this innovative medicine

II. Impactful collaboration to Treat to Beat breast cancer

In 2023, Novartis began work with Network 18, one of India's largest media houses, as part of their 'Sanjeevani: United against cancer.' Together, they launched **'Treat to Beat' to reduce fear and stigma towards a cancer diagnosis and empower individuals through their treatment journey.**

Through the initiative they have reached over 300 million people to raise awareness and understanding about life after being diagnosed with breast cancer. While screening awareness is high, there is limited understanding of life post-diagnosis. The initiative highlighted how advancements in science and healthcare are improving individuals' journeys to combat cancer.

Novartis also worked with the state governments of Rajasthan and Uttar Pradesh to start a dialogue on how the stakeholders including the state healthcare ecosystem can come together and do better for patients.

'Treat to beat' is their message of hope to breast cancer patients



Launch of Treat To Beat, a part of Sanjeevani – United for Cancer by Network18

Novartis in Society

Through their CSR interventions in 2024, Novartis in India moved towards fostering long-term, holistic impact aimed at enhancing community well-being. Their focus is on empowering communities to become happier, healthier, and more self-sufficient. In this year, they had the privilege of positively influencing over 200,000 lives through their community-first approach and strategic partnerships.

I. Water Stewardship: 360-degree model of sustainability-

Novartis is committed to the countries in which they operate. There's a direct link between health and water, they strive to act as responsible water stewards in all their locations, working diligently to attain water sustainability and ensure sufficient and safe water access.

The Watershed Development Project in Telangana adopts a holistic approach to enhance water security, sustainable agriculture, economic development, and community well-being. In its first phase, the company neutralized 100% of their water consumption while positively impacting 20,000 lives.



Desilting a river – the change from 2021 to 2023 for Telangana project

This project has increased water storage capacity by 260,014 m³ and involved planting over 10,000 trees, resulting in a 10% increase in incomes and improved health outcomes, leading to a happier, healthier community overall. Following this success, they are expanding the project to ten villages in Maharashtra, which face severe drought and flooding that hinder agriculture and access to clean water. This marginalized tribal community relied on only two wells, forcing women to walk up to 1 km multiple times a day to fetch 50 liters of water. In the second phase of their Maharashtra initiative, they effectively constructed two check dams and rejuvenated a pond, enhancing water harvesting for 68 farmers. The project has water at its core and the communities at the heart, focusing on addressing various aspects of development.



The impact on the community



II. Sustainable livelihoods for the community and for people at high risk of unemployment-

Despite being declared leprosy free almost two decades ago, the prevalence of leprosy continues to rise in India accounting for over half (almost 60%) of the global leprosy load.

Novartis has have been on a journey to champion sustainable livelihoods for people affected by leprosy with a project that is being executed by The Leprosy Mission Trust of India (TLMTI). They realized the importance of bringing people affected by leprosy (either directly or those who come from leprosy families) back into the mainstream. This project provides certified vocational skill-building, soft skills training, on-the-job experiences and set up Self Help Groups (SHGs), with an aim to empower the affected individuals with opportunities for rehabilitation and livelihood advancements.

The project has directly impacted nearly 300 individuals, creating a positive ripple effect on their families. The goal is not only to foster inclusion but also to challenge stereotypes associated with leprosy.



Beneficiaries in Training





Development hub in India launches NEST for students, start-ups and incubators

NEST (Nurturing Excellence Strengthening Talent), an initiative by Novartis is led by the Development Hub in India and aims to nurture the brightest minds in data science and technology. NEST aligns with Novartis' focus on leveraging data science and technology capabilities in India and reinforces its commitment to empowering talent to drive meaningful change in healthcare.

The ongoing competition witnessed an overwhelming response at the registration stage. Post several rounds of assessment and mentoring, finalists stand a chance to win cash prizes, bag pre-placement interviews and more at the grand finale is scheduled for February 2025.

This initiative reinforces Novartis' commitment to innovation and collaboration by encouraging talented participants within India to solve real-world cases using technology to enhance efficiencies in clinical development for life-saving medicines. It is a testament to Novartis' purpose-driven approach, combining the power of people, data, and technology to reimagine medicine to improve and extend people's lives.



NEST campus launch engagement activities at BITS, Pilani.



Novartis Development Hub in India Head Sadhna Joglekar addressing the students at BITS, Pilani.

Novartis Corporate Center, Hyderabad conferred Gold Standard

Novartis is extremely proud to share that it has been recognized with the “Pinnacle of Excellence” award in the “Gold Standard GCCs” category at the Global Capability Centers (GCC) Innovation Summit 2024 at T-Hub, Hyderabad. This recognition is a testament to the outstanding contributions their teams have made in driving innovation and excellence, behind a strong legacy of two decades. They feel extremely humbled to emerge as a key player in shaping the future of Global Capability Centers in India, setting high standards across the industry.



Government of Telangana dignitaries presenting the award to Novartis GCC representative

SheLeads Celebrating Women in Leadership

Gender equity and inclusion is a continued commitment for Novartis. They strongly believe in equal pay for women and men for work of equal value, and are committed to maintain gender balance in management and close the overall pay gap for its people.

In line with this commitment, Novartis recently hosted the SHELeads Celebrating Women in Leadership discussion on “Bridge the Divide: Empowering Gender Equality in the Workforce” at their Novartis Corporate Center in Hyderabad. The event brought together industry leaders to discuss topics such as identifying gender-based talent gaps, adapting new talent strategies, and preparing for an equitable future.

The conversations and discussions that stemmed from this day are a step forward in their collective journey to equity, helping them ensure all their people irrespective of gender have a chance to thrive, grow, and contribute meaningfully to the workplace and beyond.



Champions advancing the women's agenda from Novartis and the Industry

5th Consecutive Gold Employer Award in the India Workplace Equality Index - Creating better workplace equity and the role of ERGs

To create a workplace that truly embraces diversity, it is essential to encourage a culture where every employee feels valued. This belief guides their approach to LGBTQ+ inclusion—and their commitment was recently honoured with a fifth consecutive Gold Employer award in the India Workplace Equality Index (IWEI) 2024.

This achievement reflects their effort to build a workplace that's inclusive by design, where everyone, regardless of identity or orientation, knows they belong. To help make this a reality, they've introduced policies that promote inclusivity, created learning modules to spread awareness, and fostered open dialogues to deepen understanding within the workplace.

Their journey is also driven by their Employee Resource Group, AGLOW, a thriving community that supports employees and allies alike. With over 100 members in India alone, AGLOW actively hosts events, runs awareness programs, and champions policies that support LGBTQ+ inclusion.

Earning the Gold Employer award serves as both recognition and motivation to continue championing equality. Novartis is excited to build on this foundation, ensuring that every individual can thrive in a workplace that respects their unique journey.



Driving Change in the Lives of People Living with Serious Chronic Diseases

Novo Nordisk India continues to drive change to make the lives of people living with serious chronic diseases better. Last year was the year of going beyond and the initiatives taken up by the organisation are proof enough.

Weight of Diabetes - India, which has over 101 million individuals with diabetes (INDIAB), faces a significant challenge in managing uncontrolled glycaemic levels.¹

Given this critical scenario and increased use of the internet for the consumption of health information, there is an urgent necessity to raise awareness about diabetes and its associated impacts. In response, Novo Nordisk India launched a comprehensive disease awareness initiative titled **Weight of Diabetes**. This campaign aims to shed light on diabetes and its complications, specifically targeting people living with the condition.



The campaign *Weight of Diabetes* aimed at shedding light on diabetes and its complications, which ran for a span of 6 months generated over 20 million impressions.

1. Anjana RM et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *The Lancet Diabetes & Endocrinology*. 2023 Jul 1;11(7):474-89.

A multi-channel social media approach was employed using YouTube, LinkedIn and Meta. It featured over 75 content pieces and ran for a duration of six months. Impressively, the campaign generated over 20 million impressions, garnered 20,000+ playlist views on YouTube and attracted 700,000+ visits to the awareness website. Notably, the campaign achieved a remarkable 90% overall positive sentiment among its audience.

NovoHealth@EmbassyManyata - Obesity is a chronic disease that can seriously impact an individual's quality of life and wellbeing. To create awareness around obesity and promote health at workplace the philanthropic arm of Novo Nordisk India, Novo Nordisk Education Foundation (NNEF) has entered into a one-of-a-kind partnership with Embassy REIT called **NovoHealth@EmbassyManyata**. A formal memorandum of understanding signed on World Obesity Day, 4 March 2024 cemented this commitment. The project has garnered an exceptional response, boasting over 2,700 registrations and active engagement from 40+ companies housed within Embassy Manyata, resulting in an impressive collective distance covered of over 20,000 kilometres in a span of nine months. This impactful social endeavour, aimed at fostering community health earned the endorsement of the Government of Karnataka with the presence of Shri Dinesh Gundu Rao, Minister of Health and Family Welfare, Karnataka.



MoU signing ceremony at the launch event held on World Obesity Day, March 4th, 2024 at Embassy Manyata Tech Park in the presence of Shri Dinesh Gundu Rao, Minister of Health and Family Welfare, Karnataka and former MP, Shri Rajeev Gowda, along with Mr Vikrant Shrotriya, Managing Trustee, NNEF and Mr John Dawber, Corporate Vice President, NN-GBS.

Tour de Diabetes - With the mission to educate, empower & inspire people living with diabetes, a joint awareness and advocacy project - **Tour de Diabetes** with Novo Nordisk's Type 1 diabetes ambassador and pro cyclist Logan Phippen was spearheaded by Novo Nordisk India, Novo Nordisk GBS and Team Novo Nordisk.

This initiative not only marks their commitment to spread awareness around diabetes but also brings various stakeholders together including children living with type 1 diabetes, leading healthcare professionals, type 1 diabetes advocates, policymakers, communities, support group and eminent diabetes organisations across Goa, Mumbai, Delhi and Bangalore.



Team Novo Nordisk pro cyclist Logan Hippen, with people living with diabetes, leading the cyclothon aimed at creating awareness around diabetes management.

India's first Sickle Cell Wellness Hub - Sickle Cell Disease (SCD) is a chronic and debilitating condition that significantly impacts the quality of life of affected individuals.² India has a high prevalence of Sickle Cell Disease, particularly among certain tribal populations.³ SCD imposes a significant burden on the healthcare system and the economy due to frequent hospitalisations, loss of productivity, and long-term care requirements.⁴ To address this situation NNEF has signed a **memorandum of understanding (MoU)** with the Rabindranath Tagore Medical College in Udaipur and established **India's first Sickle Cell Wellness Hub** for holistic sickle cell disease care. This public-private partnership (PPP) aligns with the Government of India's commitment to eradicate Sickle Cell Disease from India by 2047, as part of its National Sickle Cell Anemia Elimination Mission 2023.

MoU to advance clinical trials in India - Novo Nordisk India has also signed an **MoU** with Siddhartha Medical College & General Hospital in Vijayawada and Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, to **advance clinical trials in India**. This partnership aims to drive innovation and transform the clinical research landscape, ultimately improving patient outcomes. This **first-of-its-kind three-year MoU for clinical trials** with a medical institute in the region opens doors to long-term collaboration focusing on exploring solutions in cardiology, obesity, nephrology and rare diseases by leveraging Novo Nordisk's therapeutic expertise and the institute's medical infrastructure.

2. Martinez RM et al. National Academies of Sciences, Engineering, and Medicine. Complications of Sickle Cell Disease and Current Management Approaches. In: Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action 2020 Sep 10.

These strategic endeavors underscore Novo Nordisk India's dedication to **education, advocacy, and innovation**, uniting diverse stakeholders and shaping a transformative path toward holistic disease care and improved patient outcomes across the nation.



NNEF has signed an MoU with the Rabindranath Tagore Medical College in Udaipur to establish India's first Sickle Cell Wellness Hub for holistic sickle cell disease care.



MoU signed with Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura, to advance clinical trials in India.

Quality. Trust. Wellbeing.

Otsuka Pharmaceutical India Private Limited (OPI), based in Ahmedabad, is the fully-owned subsidiary of Japanese MNC Otsuka Pharmaceutical Factory (OPF). OPI is powered by the 100+ years of Otsuka Quality legacy and is one of the leaders in intravenous nutrition products in the country. OPI has one of the largest state-of-the-art Sterile Parenteral Formulation manufacturing facilities in the IV industry. They Make in India their world-class products, which are supplied to private and Government hospitals across India as well as are exported to more than 60 countries worldwide.

The year 2024 was a milestone year for Otsuka Pharmaceutical India Pvt. Ltd. (OPI), as the organization entered a new era of change in leadership with a new CEO, Mr. Parag Swadia at the helm.

OPI is determined to take it forward by being a worthy contributor to its vision of the holistic well-being of the world we live in. In the year 2024, the company has focused on the vital aspects Safety and Quality, as well as well-being of the environment and the people. This included health check-up of employees, tree plantation, Yoga camp for employees, SHINKA- the quality mindset training, and most importantly, ANZENDAIICHI (Safety First) program with a series of activities and training to fortify and build safety culture that transcends in every facet of their work life and life beyond work as well.

In this New Year, OPI with is resolute to ensure well-being of India and the world with Otsuka's philosophy of "Otsuka people creating new products of better health worldwide."

Celebration of New Era and Town Hall (Takagi San visit)



Go Green With Otsuka – Tree Plantation at OPMF



SHINKA- the quality mindset training



Anzendaichi – Safety First Initiative



Health Check-ups of employees



Yoga Week





Committed to Building a Healthier India

Pfizer's India strategy is rooted in addressing the country's diverse healthcare needs through patient-centric innovation. Its journey has been marked by several significant contributions, from pioneering vaccines and treatments in critical therapeutic areas to establishing a strong commercial, manufacturing and R&D presence. The company's commitment to India continues to evolve, with a focus on enhancing healthcare, improving access to its therapies and vaccines and making a meaningful difference in the lives of patients.

As Pfizer embarks on its 75th year in India, it is committed to building a healthier future through its unwavering focus on collaboration, care, and innovation for India.

Delivering on the Purpose to Bring Breakthroughs that Change Patient Lives

Pfizer is committed to delivering on its purpose to bring breakthrough solutions in oncology, vaccines and across other therapeutic areas to improve the quality of lives for patients and their families.

2024 was marked by several notable achievements that began with their partnership with Glenmark Pharma to introduce a novel treatment for atopic dermatitis in India. This partnership has helped leverage the combined strengths and capabilities of both organizations to make innovative therapies accessible to patients and healthcare providers across India.

At the ASCO, Pfizer also announced groundbreaking results from the 5-year follow up of its Phase 3 CROWN study of lorlatinib for ALK+ advanced Non-Small Cell Lung Cancer (NSCLC). The study revealed that 60% of patients achieved five years of progression-free survival (PFS) with one of Pfizer's novel oncology treatments.

Expanding adult vaccination coverage

Pfizer in India continued its focus on expanding adult vaccination coverage by launching new Centres of Excellence (CoEs) across the country. These CoEs, established in collaboration with leading hospitals, are designed to enhance community protection against vaccine-preventable diseases, including pneumococcal vaccination, by promoting the adoption of adult vaccination. Pfizer aims to address the low vaccination rates in India, particularly among adults, and is providing advanced training, resources, and educational initiatives for healthcare professionals.



Supporting healthcare innovations

The Government of India is supporting the healthcare industry through policy interventions like the Research-linked Incentive Scheme (Promotion of Research and Innovation in Pharma MedTech Sector-PRIP) for promotion of R&D in pharma. Pfizer and Social Alpha collaborated with the National Institute of Pharmaceutical Education & Research (NIPER), Ahmedabad, to launch a special edition of its INDovation program. Through this initiative, Pfizer provided funding of INR 25 lakhs to six young healthcare startups, along with incubation facilities at NIPER Ahmedabad. Supported by the Department of Pharmaceuticals (DoP), Pfizer's INDovation program emphasizes the commitment to indigenous healthcare solutions, aligning with the nation's healthcare priorities and fostering positive social impact. This is one of the largest such programs, both by grant value and partnerships.

The INDovation winners were announced by Dr Arunish Chawla, Secretary, Department of Pharmaceuticals, Government of India



Working for our communities – Project Parivartan and Project Aastha

Pfizer, in collaboration with the Government of Goa, Goa Medical College and Hospital (GMC), Directorate of Health Services (DHS), and Americares India Foundation, launched Project Parivartan. The initiative aims to combat antimicrobial resistance (AMR) and strengthen infection prevention and control (IPC) in Goa's public healthcare facilities. It aligns with India's National Action Plan on AMR and WHO's global health priorities.

By uniting expertise, resources, and shared vision, this initiative builds on Pfizer's efforts to drive systemic improvements in infection prevention and control.



The initiative was inaugurated by Goa Minister for Health, Vishwajit Rane.



Project Aastha Rare Disease is a CSR initiative by Pfizer and implemented by DFY, is a program that works to provide aid to Rare Disease patients during their diagnosis, treatment, and rehabilitation phase. The Project is aimed at establishing a support system that facilitates the best available care to Rare Disease patients. As part of this project, Pfizer has set up helpdesks at four centers of excellence. These helpdesks are a step towards the betterment of the community and Pfizer aims to serve the patients with care and support.

Driving Growth through Best-in-Class Analytics, Top Talent, and Innovation

Pfizer inaugurated its first-ever dedicated commercial analytics center, the Analytics Gateway, in Mumbai. The Analytics Gateway represents a significant milestone in Pfizer's international commercial strategy and is positioned to be a global capability centre serving all of Pfizer's international (ex-US) markets to bring analytics, and insight breakthroughs that will benefit patients.





A healthier future. It's what drives us to innovate.

At Roche, this motivates them to continually innovate, advancing science and ensuring everyone has access to the healthcare they need—today and for generations to come. The goal is to build a world where every person can enjoy more time with the people they love, and live healthier, fuller lives.

For over 125 years, Roche has taken on some of the most complex challenges in healthcare, responding to the ever-evolving needs of people around the world. Today, Roche stands as one of the world's largest biotech companies, a leader in in-vitro diagnostics, and a global supplier of transformative, innovative solutions across major disease areas.

Their unwavering commitment to science drives their ambition to deliver better outcomes for more patients, faster. The company is committed to facilitating rapid, broad, and sustainable access to its innovations, ensuring that the benefits of their work reach every corner of the globe. Together, they strive to convert today's knowledge into tomorrow's therapies—making a difference for patients now and in the future.

1. Product Launches

For more than 60 years, Roche has been committed to making a difference to the lives of people in India. From being a key distribution market for the iconic cough syrup Sirolin, to manufacturing vitamins in the late 1950s, to the introduction of advanced targeted and immunotherapy medicines for treating different forms of cancer to foraying into newer therapy areas of Ophthalmology and Neuroscience in their endeavor to bring the most innovative and path-breaking drugs to Indian patients.

Ocrevus Launch

- ◆ Roche Pharma India launched its blockbuster breakthrough drug, Ocrevus (Ocrelizumab), for the treatment of multiple sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of numerous patients grappling with this debilitating disease in India. Launch of Ocrevus, Roche's flagship globally, in India underscores its commitment to providing innovative solutions to address patients' needs.
- ◆ Ocrevus is the first and only approved Disease Modifying Therapy (DMT) for both Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS).
- ◆ First and only approved High efficacy therapy with more than 3 lakh patients treated globally, approval across >100 countries and with 10-year long term safety and efficacy data



Polivy Launch

For the first time in nearly two decades, there has been a groundbreaking advancement in DLBCL treatment with a new drug: Polatuzumab in combination with chemotherapy. This is the first FDA- approved therapy in nearly 20 years for the first-line treatment of Diffuse Large B-Cell Lymphoma (DLBCL), a hard-to-treat disease and the most common form of non-Hodgkin lymphoma (NHL). Globally, over 55,000 patients have been treated, and the drug is now approved in 102 countries, underscoring its worldwide impact.





Vabysmo Launch

A global pioneer in healthcare, Roche launched a revolutionary advancement in the treatment of retinal conditions with Vabysmo®, the first injectable eye medicine designed to address unmet needs in patients suffering from macular macular edema, neovascular wet age-related macular degeneration (nAMD) and diabetic macular edema (DME). Vabysmo® represents a significant milestone when it comes to vision care, offering a unique mechanism of action (MoA) and potential benefits for individuals and their caregivers. This ground-breaking therapy represents a major advancement in the battle against vision loss and improve their vision.



2. The Blue Tree (TBT) Program – A Year of Impact

Roche Pharma India's The Blue Tree (TBT) program has made a profound impact, offering comprehensive support to patients battling cancer, hemophilia, and rare diseases. In 2024, the program assisted over 10,000 patients, bringing the total to more than 20,000 beneficiaries since its launch.

TBT provides a range of services including physiotherapy, nutritional counseling, financial and insurance guidance, and disease awareness materials. In the past year alone, the program facilitated over 2,500 diagnostic tests and conducted 3,500+ counseling sessions, addressing both the medical and emotional needs of patients.

The Patient Assistance Program (PAP) was a key highlight, with over 40,000 cold chain deliveries, ensuring timely access to critical medications. Besides, TBT launched a no-cost EMI option for all products, helping overcome affordability challenges and improving access to essential treatments. The program continues to strengthen its commitment to patient care, offering holistic support throughout patients' treatment journeys.

3. Clinical Trial Excellence Project - Site AIR (Advancing Inclusive Research) alliance – Advancing Clinical Research in India

In a bid to strengthen the capabilities of public health institutions and ensure access to global innovations, Roche Pharma India launched its Clinical Trial Excellence Project - Site AIR Alliance. Over the past year, Roche partnered with nine leading cancer centers across India to elevate their clinical trial capabilities in line with global standards.

This initiative focuses on training research teams, enhancing processes, and digitizing dossier submission and review by Ethics Committees, ensuring high-quality clinical research that prioritizes patient safety. By positioning these centers as Centres of Excellence for Clinical Research, the project fosters innovative treatments and supports India's healthcare sector growth.

Through this collaboration, Roche is not only empowering institutions with advanced clinical and digital skills but also driving a transformative impact on the healthcare landscape, ensuring patients in India gain access to cutting-edge therapies.





4. Roche Customer Experience Centre – Revolutionizing Healthcare Engagement

Roche Pharma India's Customer Experience Centre (CX) has made significant strides in leveraging India's tech talent and frugal innovation, delivering high-quality content at a fraction of the cost. This has facilitated cross-country collaborations and content efficiency, showcasing India's differential advantage in the global healthcare landscape.

In 2024, CX delivered over 2,000 immersive experiences across more than 50 touchpoint events and 20 conferences, with an exceptional customer satisfaction score of 4.7/5. With CX hubs set up in major Indian cities, such as Chennai, Kochi, and Bengaluru, the initiative has opened doors for patient journey partnerships with government institutions, private hospitals, and healthcare ecosystems like ESI and state governments.

Roche India's CX continues to provide valuable guidance to Roche HQ and other affiliates on customer engagement, content development, and storyboarding. Through innovative partnerships in immersive content development and digital solutions, CX is driving better patient outcomes by creating immersive experiences using VR, AR, MR, and other technologies.

By integrating data analytics and leveraging a comprehensive overview of customer preferences, Roche's CX is transforming the healthcare experience, fostering learning, and facilitating seamless execution of impactful experiences that improve patient care.





5. CSR Initiative

Project SWACHH - A Step Towards Sustainable Waste Management and Community Health in Haridwar

Haridwar, Uttarakhand, faces significant challenges in managing 65 lakh tonnes of municipal and biomedical waste annually, impacting public health and the environment. Roche Pharma India's Project SWACHH aims to transform waste management by partnering with Bulk Waste Generators, focusing on segregation, composting, and public education for sustainable solutions.

Key Components of Project SWACHH:

The **Bio-Composting** Initiative installed 240 composters across 156 BWC sites, diverting 312 tonnes of waste annually, producing 124 tonnes of compost. This reduces waste, supports local income, and fosters sustainability.

Public Education and Awareness: The IEC campaign educates the public on waste management, empowering residents and businesses to engage in segregation and composting for long-term sustainability.

Economic Empowerment: Project SWACHH empowers local self-help groups to sell compost, generating USD 11,500 in revenue, promoting entrepreneurship and community welfare.

Programme Achievements:

Infrastructure and Impact: 240 bio-composters at 156 BWC sites convert 312 tonnes of waste into 124 tonnes of compost annually, reducing amount of waste sent to landfills and promoting sustainability.

Environmental Benefits: The project is projected to reduce CO2e emissions by 19.9% in 10 years, equivalent to removing 1,403 cars from roads annually.

Sustainability and Long-Term Impact: Project SWACHH strengthens Haridwar’s sustainable waste management, fostering a circular economy through community involvement and government ownership.



St. Jude India Child Care Centres - A Partnership for a Better Tomorrow

In line with its commitment to making a positive and lasting impact on society, Roche has partnered with St. Jude India Child Care Centres in Mumbai and Guwahati to provide holistic care for children undergoing cancer treatment, along with support for their families. The objective of this partnership is to offer a “home away from home” environment, where children battling cancer and their families can find a safe, hygienic, nurturing space that enables them to focus on recovery and well-being.

The Mission and Impact: Roche’s partnership with St. Jude India has directly touched the lives of nearly 400 children and their families.

In the Guwahati Centre, approximately 35% of the beneficiaries are girls, a demographic that often faces additional challenges in healthcare access. These children, many coming from economically disadvantaged backgrounds, face malnutrition and inadequate care prior to their cancer treatment.

Interventions at the Centres:

- ◆ Safe, Secure, and Hygienic Accommodation
- ◆ Nutritional Support
- ◆ Transport Facility
- ◆ Education and Learning
- ◆ Emotional Support
- ◆ Celebrations and Cultural Exchange
- ◆ Recreational Activities for Children
- ◆ Engagement Activities for Parents



In India... for India and the World

Sanofi is chasing the miracles of science to improve people's lives. For over six decades, their steadfast commitment to improving lives in India has driven their pursuit of innovative and accessible healthcare solutions. Anchored by a robust brand portfolio spanning key therapeutic categories, they help people manage their diverse health challenges.

Over the last couple of years in India, Sanofi has channelled energies across four strategic pillars: diabetes, transplants, specialty care and an optimized go-to-market approach, and made significant strides in enhancing healthcare outcomes, nationwide.

Fuelled by a resolve to bring their best-in-class and first-in-class innovative products to India, in 2024 they successfully launched Soliqua® - their best-in-class diabetes drug for the premix segment. Soliqua® is showing immense promise in significantly reducing the complexities of living with diabetes. Encouraged by positive patient outcomes, they already have the faith and confidence of thousands of doctors who continue to prescribe it.

Some of their key recent milestones/achievements of 2024 include:

Goa Manufacturing Site celebrated 26-glorious years:

Among India's leading manufacturers of an extensive range of innovative medicines across vital therapeutic areas, their regulatory compliant and state-of-the-art in-house manufacturing facility in Goa (India) celebrated 26-glorious years in 2024. With a total capacity of 5+ billion tablets in FY2023, the site has also outlined a comprehensive plan to optimize manufacturing processes, ensuring data integrity and reliability. This Sanofi Goa unit holds a distinctive status as the sole facility, aside from the one in Sanofi Frankfurt, authorized to produce Ramipril PC granules. Additionally, the facility is gearing up to introduce new products seamlessly transferred from other sites, demonstrating its commitment to remaining at the forefront of pharmaceutical innovation and diversification. Notably, the plant targets achieving DIRA (Data Integrity Risk Assessment) compliance by 2025,

highlighting their efforts towards staying ahead of industry trends and leveraging technology for sustainable growth. Additionally, the Goa site has just completed upgrading the facility to be a state-of-the-art facility with the introduction of PAL-MAL (Personnel Air Lock and Material Air Lock) for the entire production area. Complemented by a robust network of contract manufacturing partners across the country, their Goa site enables them to deliver innovative and high-quality affordable medication with efficiency and scalability. Sanofi Goa site has consistently maintained its Status of being a best-in-class low-cost manufacturing unit for Sanofi, with > 99% customer service levels in India and abroad.



Goa Manufacturing Site celebrating 25-years

State-of-the-art Global Capability Centre launched in Hyderabad:

The expansion of their Global Capability Centre (GCC) in Hyderabad, makes it the largest of Sanofi's four global hubs. Over the next two years, this GCC (hub) will expand to host up to ~2600 employees. Established in 2019, the Hyderabad hub has grown exponentially from being a Medical Hub to now providing several best-in-class services to Sanofi's global functions and affiliates across the world. This future-forward global hub for talent in Hyderabad, is a state-of-the-art workplace designed to be environmentally sustainable and foster diversity and inclusivity.



Inauguration of Sanofi's Hyderabad Global Capability Centre

(standing from left to right): Jayesh Ranjan Spl. Chief Secretary, Govt. of Telangana, Arunish Chawla Secretary, Dept. of Pharmaceuticals, Govt. of India, Madeleine Roach Executive Vice President - Business Operations, Sanofi, Hon'ble Minister D. Shridhar Babu Minister of Industries and IT, Govt. of Telangana, Thierry Berthelot Consule General, Consulate of France (Bengaluru), Emmanuel Frenehard Executive Vice President, Chief Digital Officer, Sanofi, Mrinal Duggal Head of Sanofi GCC, Hyderabad

Their CSR Programs are showing impact...and winning:

Their CSR policy focuses on non-communicable diseases (NCDs) where they bring in their rich experience and resources. All their CSR initiatives are meticulously executed by their in-house team in collaboration with NGOs, implementing partners and State Governments. This approach ensures the effectiveness and reach of their social responsibility endeavour.

- ◆ Fully-equipped **Medical Mobile Vans** deployed across **500 villages** & urban slums in Maharashtra offer **free screening, diagnosis, treatment and disease awareness** to approx. **4,30,000 people** for NCDs and referral services. **Winner of Indo French Chamber of Commerce & Industry award for the Best CSR Project of the Year & 'Doing Good for Bharat' Awards 2024**



Mobile Medical Units (MMUs)



Type 1 Diabetes (T1D)

- ◆ Their **Type 1 Diabetes Program (T1D)** in partnership with RSSDI is helping **1400+ underprivileged children** living with T1D manage their condition better. **Winner of 5th ICC Social Impact Summit & Awards 2023, Sanofi was declared 'Winner' in the Healthcare category for its Social Impact Program for Type 1 Diabetes**


- ◆ Their **KiDS (Kids & Diabetes in Schools)** program imparts education & engagement amongst **2,00,000 children**, teachers and parents across **500+ schools** to help curtail the overall long-term disease burden in Goa & Uttar Pradesh. **Winner of Jury Choice Award in the Healthcare category at 6th Indian Chamber of Commerce Social Impact Summit & Awards 2024**



Kids & Diabetes in Schools (KiDS)

Sanofi in India won 3 CSR awards in 2024

KIDS



Indian Chambers of Commerce & Industries - The prestigious Jury Choice Award in the Healthcare category

Mobile Medical Units (MMUs)



Winner at the Doing Good for Bharat Awards at Asia's largest CSR conclave

Mobile Medical Units (MMUs)



Winner at the Indo French chamber of Commerce and Industry. Awarded the Best CSR Project of the Year

As they progress on their journey, they continue to be guided by their purpose – chasing the miracles of science to improve people’s lives. By cultivating expertise, capability, and capacity, they will continue to elevate patient and consumer experience and deliver shared value to all their stakeholders and make a lasting impact on India’s healthcare landscape.

The access to treatment and care goes beyond just pricing; and companies can play a pivotal role in creating innovative channels and pathways to provide medicines to patients.

Sanofi’s India Charitable Access Program (InCAP) – which part of Sanofi’s Global Humanitarian Program – is an outstanding example of their relentless pursuit to provide transformative therapies to people, who have a demonstrated need, meet the program’s criteria, and otherwise would not have access to such treatments.

The first & longest-running program of its kind for people with lysosomal storage disorders, the program has benefitted patients in over 100 countries, and over 150 new patients are approved annually.

Patients from India first started receiving therapy under the humanitarian program in 1999, and in 2007, they started the India Charitable Access Program (InCAP) through which they started providing free treatment to people in India afflicted with the following Lysosomal Storage Disorders (LSDs) – Gaucher, Pompe, Fabry and MPS Type I. In 2022, when the first and only therapy for ASMD was launched globally, people in India started receiving the therapy under their humanitarian program.

India was one of the earliest countries to participate in the Rare Humanitarian Program, and over the last 25 years, 300+ people have received treatment under their humanitarian program in India.



Deepesh – living with Gaucher

Lavanya – living with MPS Type 1



Ketki – living with Gaucher



Sanofi India at Annual RSSDI Conference

The **Sanofi India Diabetes Team** made an impactful presence at the **Annual RSSDI Conference** (**R**esearch **S**ociety for **S**tudy of **D**iabetes in **I**ndia) engaging HCPs about their best-in-class & first-in-class product portfolio. The stall was visited by renowned HCPs keen to engage with their teams and understand more about **Soliqua® – the newest kid-on-the-block, offering** – once-daily solution that breaks through the complexity of living with type 2 diabetes.



Sanofi stall at RSSDI

Bringing Hope to Cancer Patients in India

Servier is a global pharmaceutical group founded with a simple mission: to serve health. Governed by a non-profit foundation, they are driven by a commitment to creating a meaningful social impact—both for patients and for a sustainable world. With over 21,400 employees worldwide, they remain steadfast in their dedication to therapeutic progress, responding to patient needs and healthcare challenges. Their unique governance model, which allows them to reinvest more than 20% of their turnover into research and development, empowers them to innovate with a long-term vision. Guided by their independence and responsibility, they are shaping the health of today and tomorrow, delivering medicines to over 150 countries.

Oncology: Ambition at Servier

Servier is committed to tackling hard-to-treat cancers and improving patient outcomes. They focus on developing innovative therapies for:

- Digestive cancers
- Glioma
- Hematologic cancers

The aim is to address unmet medical needs, improve survival rates, and enhance patients' quality of life. Oncology is central to their R&D strategy, with over 70% of their budget dedicated to advancing immuno-oncology and targeted therapies for aggressive cancers. Given that cancer is the second leading cause of death globally, Servier's oncology focus is vital to their mission of addressing one of the world's most pressing health challenges.

India: A Key Focus for Cancer Care

India, with its vast population and high cancer burden, is central to Servier's goal of delivering innovative and affordable healthcare solutions by 2030. With over 14 million cancer cases estimated in India in 2022, the country plays a pivotal role in shaping our oncology strategy. Servier is committed to improving treatment access and outcomes for patients, particularly in regions where healthcare resources are limited.

Onivyde®: Bringing Hope to Pancreatic Cancer Patients

Pancreatic cancer is one of the most aggressive cancers to treat, characterized by low survival rates and rapid progression. Patients often face significant challenges due to harsh side effects and limited treatment options.

Onivyde® represents a breakthrough in the treatment of metastatic pancreatic cancer. By targeting malignant tumor cells with a manageable side effect profile, Onivyde® improves progression-free survival and reduces treatment-related toxicity.

Servier India launched its oncology franchise alongside Onivyde® to address the needs of metastatic pancreatic cancer patients.



Their commitment to expanding treatment options continues, with upcoming products in the pipeline targeting acute myeloid leukemia, cholangiocarcinoma, myelodysplastic syndromes, and gliomas.

Servier's Commitment to Patients

Servier believes that no patient should be left behind. To ensure equitable access to treatment, they have introduced nationwide patient assistance programs designed to make cancer therapies more affordable and accessible across India. These programs focus on the "self-funding" category, where patients often face financial barriers to treatment, reinforcing their commitment to providing meaningful and accessible treatments.

Servier's Iconic CSR Project with CanKids: Driving Impact Through Employee Engagement

Their commitment to social responsibility extends beyond medical treatments. In 2023, Servier India partnered with CanKids...KidsCan, a national NGO working to improve the care and support for children battling cancer. Through this partnership, they are supporting 540 children at CanKids Hospital Support Units (CHSU) across India, ensuring they receive top-tier treatment, emotional support, and enhanced healthcare capacity.

This initiative is not just about funding; it's about creating a lasting impact. Over 150 employees have volunteered to actively engage in activities like skill-building workshops, quizzes, poster-making, rangoli, and origami, which provide joy and comfort to the children and their families during difficult times. This engagement is a testament to Servier's belief that employees can be catalysts for change and reinforces their commitment to making a difference in the community.

By linking their employees to meaningful causes, Servier fosters a sense of purpose and fulfillment, while enhancing the well-being of those they serve. This initiative underscores their belief in the power of holistic care and community connection, making a tangible difference in the lives of children battling cancer.

Through these efforts, Servier India continues to demonstrate its commitment not only to treating difficult cancers but also to improving the lives of patients and communities across India.





Collaborating to create a Better Healthier World

Founded in Mumbai in 1961, ACG has carved a niche for itself, rising to become the world's largest integrated supplier of solid dosage products and services to the pharmaceutical and nutraceutical industry. ACG's expertise in the former - from providing capsules, to manufacturing machinery and equipment, to protective packaging materials, to traceability solutions, and dedication in the latter, have led ACG to have a formidable presence in 130+ countries globally..

Caring for the community; working for the community.

At ACG, community always comes first. Which is why ACG takes its CSR very seriously. In 2015, the company set up the ACG Cares Foundation to implement its various CSR activities efficiently, engaging all stakeholders sincerely, in a systematic, inclusive manner. ACG has delineated several initiatives, some long drawn, some short-term, all with the aim of bettering society, in an equitable, sustainable manner. The focus of these projects has been in the areas of environment, education, health, livelihood and sports.



Striving to shape a cleaner, greener world.

ACG has three on-going projects in Shirwal, Maharashtra, that aim to create impact, improve conditions and instigate better practices.

Climate Change Adaptation

Climate change is a significant issue, and ACG addressed it through a program focusing on crop diversification, sustainable water management, renewable energy, improved soil health, and carbon sequestration, while promoting women's livelihoods. The initiative affected 285 households, planting 5,000 trees on 25 hectares of barren land. A solar energy system reduced CO2 emissions by 10.9 tons for 318 households, and IRESA Biogas families saved ₹137,070, cutting CO2 emissions by 73.92 tons annually compared to wood.



Watershed Management Project



The villages around Shirwal faced significant water challenges, with heavy surface run-off during monsoons causing soil erosion and drought leading to water scarcity in summer. To tackle these issues, ACG initiated an integrated watershed management project to improve rainfed and degraded land, strengthen community institutions, and enhance project effectiveness in six villages. As a result, 279 lakh litres of water are now conserved, the groundwater table has risen, and year-round drinking water is available. A total of 294 hectares were treated, and communities have also been educated on the benefits of soil and water.

Kitchen Waste Management Project

In the project, community members receive composter planters and training to convert household organic waste into compost for growing vegetables. After two years of successful execution, gram panchayats are involved to ensure sustainability. Since 2016, ACG has worked in seven villages, benefiting 1,790 households with composting planters. The initiative has treated 1,157 tonnes of kitchen waste, producing 115.7 tonnes of organic compost.

Integrated Waste Management

- ◆ The project aims to enhance waste management in Gram Panchayat Shirwal, Satara, by processing 15 tons of waste.
- ◆ Reducing transportation costs, implementing waste segregation at the source, and fostering community involvement through a Material Recovery Facility and Composting Center with modern machinery.
- ◆ Minimize solid waste through reuse and recycling.
- ◆ Establish a facility for waste segregation and recovery.
- ◆ Improve efficiency in waste collection and transport.
- ◆ Raise awareness about solid waste management benefits.
- ◆ Enhance staff capacity for safe and professional operations.
- ◆ Monitor and evaluate system performance regularly.



Other Achievements that bring us pride.

ACF demonstrated its commitment to the community by completing a storm-water pipeline project in Shirwal, benefiting 5,000 people by reducing water pollution and disease risk. The company also installed a 10 KV rooftop renewable energy system at Lohom PHC in Shirwal and provided 100 solar lights for street lighting in Ashagadh village, Dahanu.



Honing the Health Narrative.

ACG accords better health and improved lives with the due importance it deserves. Thus, ACG focuses a lot of its CSR on initiatives that result in a stronger, healthier, more aware population.

Better Health Program (BHP)

This extensive initiative covered 34 villages in Dahanu, Shirwal, and Talegaon, benefiting over 30,000 people. Its goals included promoting regular OPD consultations, providing free medication, and reducing anaemia in women and adolescents, as well as non-communicable diseases. The project also improved hygiene practices and increased awareness of health services, leading to higher enrolment in government schemes through the Facilitation Centre. Health Awareness Camps held in these areas screened 555 individuals for eye issues, with 73 referrals and 41 cataract operations completed at no cost. Additionally, 168 females were screened for cancer, 2,073 adolescents were checked for anaemia (1,453 identified as anaemic), and 476 children were assessed for underweight issues (371 identified as underweight), with nutritional counselling ongoing.



3329 beneficiaries were linked and benefitted from various government schemes. Details of benefits received as below -
 Direct income – **INR 1.09 crores**
 Indirect income – **INR 50.49 crores**

**Pediatric palliative care:
 Nutrition enrichment program**

ACG Cares Foundation sponsored a Nutrition Enrichment Program for 2,814 cancer-afflicted children, partnering with an NGO. After assessing for malnutrition, each child received a customized diet plan, nutritional food, and counselling, with progress monitored until they became cancer-free.



**Special Education and Multiple Therapies to
 children with Multiple Disabilities**

Children with disabilities face significant challenges, with a UNICEF report noting they are less likely to access education. ACG is supporting 24 children in Mumbai through Arogya Mitra Kendra, improving health and education for 533 adolescents. The program provides special education and therapies to enhance skills like communication and vocabulary.



Arogya Mitra Kendra

This intervention aims to improve adolescents' health indicators by empowering communities and strengthening health systems. Arogya Mitra Kendra helpdesks facilitate smoother access to treatment. The program successfully reached 533 adolescents.



Enhancing Animal Health Care Services



The Stray Care program rescues street animals in Mumbai and takes them to partner shelters for recovery. ACF aims to reunite the healed animals with their original packs. It has 13 vet clinic partners and has treated 428 animals.

Better Learning Leads to Better Livelihoods

In an effort to enable farmers and youth obtain better opportunities in life, generate more income and improve their standard of living, the foundation set about to train, educate and upskill these people through various specially formulated programs in Maharashtra.

Farm Based Livelihood

In this outreach across 6 villages and 50 hamlets in Dahanu, locals learned improved methods of vegetable cultivation, horticulture, and floriculture. The training benefited 600 families farming 600 acres, enhancing their yields. The program also focused on water resource development and soil conservation, transforming 240 hectares of uncultivable land into productive land. ACF supported 300 families in vegetable cultivation, increasing participants from 29 to 271. Additionally, 300 families engaged in floriculture, planting a total of 90000 jasmine shrubs and other flora, resulting in significant income growth for all participants.



Skill Development Program

To upskill youth from rural areas of Dahanu, Shirwal, and Talegaon, ACG provided vocational and soft skills training, covering 190 villages and training 950 youth. The initiative achieved positive results, with over 63% successfully placed in jobs.



Emphasizing Education - every student matters

A good education is a stepping stone to the future, and ACG aims to provide this opportunity to as many as possible. ACG's initiatives in education aim to encourage students to overcome academic difficulties, return to formal education and equip special learners with remediation whenever needed.

Better Learning Program (BLP)

Many students drop out due to struggles with Math, English, and Science. ACG aimed to change this by enhancing academic performance, especially in girls in grades 8-10 in Dahanu, Shirwal, and Pithampur. Poor performers from 18 schools received remedial classes, and efforts were made to engage parents and the community about the importance of education. A total of 1,177 students participated in the program, which included quarterly evaluations to track progress and ensure they completed their education.



Enabling healthcare organizations to be future-ready

Indegene Limited is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready.

Indegene is now a listed company

Indegene listed its equity shares on the two stock exchanges in India (NSE Limited and BSE Limited) by way of its Initial Public Offering (IPO). This marked a significant milestone in their journey to further strengthen their position as a leading digital-first life sciences commercialization partner. One more step towards their founding vision to build an enduring company that combines healthcare expertise and fit-for-purpose technology!



Silver Medal in ESG Assessment by EcoVadis

Indegene has been awarded the Silver Medal by EcoVadis for its ESG performance in FY 2023-24. Indegene is now in the top 15% (93rd percentile) of all companies rated by EcoVadis, an organization that has rated over 130,000 companies across 220+ industries in over 180 countries.

This achievement strengthens Indegene's resolve to further improve its ESG policies and practices, while aligning with the sustainability aspirations of all stakeholders.



Advancing scientific discoveries

Neurodegenerative diseases will become the second leading cause of death worldwide by 2040.

The Indian Institute of Science and Ignite Life Science Foundation announced strategic collaboration with Indegene to advance scientific discoveries in cardiovascular and neurodegenerative diseases space.

Enabling early-stage life sciences startups

Centre for Cellular and Molecular Platforms (C-CAMP) and Indegene announce strategic collaboration to help life science startups accelerate innovation and growth.

Indegene will bring in financial assistance, mentorship via highly skilled and specialized experts, and a digital service suite, supporting C-CAMP's efforts in nurturing at least 5-7 early-stage deep-science startups with a 360-degree ecosystem.



Empowering future leaders

Indegene contributed 110 laptops to students of Dr. HN National College of Engineering under their Ganaka 1.0 initiative.

By providing essential tools and resources, Indegene aims to enhance skills and create better opportunities for these future leaders.



Best Companies for Women in India

Indegene was recognised among the Best Companies for Women in India with a Hall of Fame distinction by Avtar The Power of Diversity and Seramount.

Indegene is proud of its women employees and committed to fostering a diverse, inclusive workplace where they thrive.



Augmenting depth of clinical and regulatory writing expertise

Indegene announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition augments Indegene's depth of clinical and regulatory writing expertise for market authorization applications globally.

Trilogy has a proven track record of more than 22 years of providing medical writing services to the biopharmaceutical and medical devices industry with strength in expertise across oncology, immunology, neurosciences, urology, anti-infectives, endocrinology, respiratory diseases, and many other therapeutic areas.



Strategic Collaboration with Microsoft

Indegene announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purpose-built, enterprise-grade Generative AI (GenAI) services, thereby driving faster innovation at scale.

Indegene and Microsoft have committed to developing resources in highly specialized and skilled medical and technology tools to co-innovate generative AI services and workflows across commercial, medical, regulatory, and clinical functions. Some of the key use cases the strategic collaboration focuses on in the first phase, include:

- Content Super App
- Future-ready medical content value chain
- Data Management and Analytics for Clinical Trials

A New Center in Hyderabad

Indegene announced a new center in Hyderabad to strengthen its global delivery operations and better address growing business needs.

India is rapidly emerging as a critical hub for global pharma companies, fueled by its vast pool of skilled medical and technology talent. These companies are increasingly seeking a partner with core domain expertise and life sciences-contextualized technology to help them scale their operations in a non-linear, technology-led way. Indegene will continue to co-innovate and collaborate deeper with its clients to help them modernize and transform their commercial, medical and clinical operations, and be future-ready.



Future-Ready Pharma GCC Summit

Indegene and T-Hub hosted the first Future-Ready Pharma GCC Summit in Hyderabad.

The event brought together senior pharma leaders and innovators to discuss the future of pharma GCCs. The global executives shared proven ideas to transform pharma GCCs into innovation hubs and exchanged thoughts on how to build future-ready GCCs.



Expediting excellence; accelerating access

Parexel is among the world's largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of their clinical, regulatory and therapeutic expertise, their team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Their depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare's most complex areas, while their innovation ecosystem offers quality solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, they work With Heart™ every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. This approach continues to earn them recognition industrywide, with Parexel being the recipient of the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships, named "Best Contract Research Organization" in November 2023 by an independent panel for Citeline, and "Top CRO to Work With" by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey. For more information, visit parexel.com and follow them on LinkedIn, X, Facebook and Instagram.

Intervention that improves lives.

Parexel believes in not just improving lives through enabling quicker access to medical breakthroughs, but by enhancing its quality through their various CSR projects. Indeed, Parexel India is deeply committed to making a difference to the community, and they do it through activities that include supporting healthcare, improving women's livelihoods, and reducing environmental impact. In the year '24-'25, the company successfully attained many such laudable goals, which has only set the bar higher for the current year!

A United approach to Uplifting Community.

Last year, Parexel partnered with United Way, Bengaluru, to further its CSR goals. The NGO has a 133-year legacy of community service and operates across 47 countries. Its Indian faction has reach across all the major Indian states; and strives to serve the community by propelling change.

Women's Livelihood Program (Hyderabad)

Through this initiative, Parexel provided retail training to 105 students from underprivileged backgrounds, hailing from different districts of Telengana. The women, almost equally divided into under graduates and graduates, received 140 hours of training, and received a certificate on completion of the program. Further, 35 students were even provided with placement as Store Executives by the end of the program.



Disha - Women Livelihood Program (Chhoti Si Asha)

This project saw the training of 35 women in crochet and embroidery, with their graduation and first mock-orders initiated. The success of this initiative has resulted in discussions with 3 additional groups for training in crochet, dari weaving, and embroidery. Parexel and United Way have also created multiple online campaigns to boost sales and livelihood opportunities for these women, as well as others, by providing employment to over 100 women in 2023-24. They have also started manufacturing collections for upcoming shows and exhibitions in Chandigarh and Bangalore.



Cleft Reconstructive Surgery (Smile Train India)

Cleft lip and palate, birth defects that occur when a baby's upper lip or palate doesn't fully develop during pregnancy, leading to visible gaps or openings, and can cause problems eating, breathing, swallowing and in speech. This condition can only be corrected through Cleft Reconstruction Surgery – a critical medical procedure – and is best done at a young age. Parexel sponsored 50 surgeries, with more than half the number being infants and the rest in the 3-18 year age group. All the beneficiaries were from underprivileged backgrounds.



Support to Sri Shankara Cancer Foundation

Parexel donated medical equipment to the Sri Shankara Cancer Foundation's centres in Bengaluru and Bhubaneswar to ensure better treatment for patients from economically weaker sections of society. The company procured Ultrasound Affinity 70 (Affinity 70 Philips) and Computed Radiography (CR) System for the Bengaluru centre, and Cobas e411 analyzer (Disk system), Automatic bacterial identificatory (VITEK 2 Compact 30 Biome Rieux) and Automated Blood and Body fluid culture System in Bhubaneswar.



Apheresis Machine Donation

The Regional Cancer Centre, Trivandrum was the recipient of an Apheresis machine from Parexel. This medical device separates blood components and is used to treat conditions like blood disorders, blood cancer, and autoimmune disorders. With this donation the hospital's capacity to handle a wide range of medical conditions gets enhanced, reducing waiting times for patients, and improving overall healthcare outcomes. It also ensures that healthcare professionals have the necessary tools to provide better care and address emergencies, especially in underserved or remote areas.



Supplies to Jyothi Foundation

Ration kits and medical supplies were donated to the beneficiaries of Jyothi Foundation in Hosur in an essential initiative aimed at supporting vulnerable communities in times of need. These kits benefited 65 families from the area.



Donation of Laptops

In an effort to facilitate greater learning and better opportunities in the future, Parexel donated 1000 laptops to students from government institutions (Schools and Colleges) in Hyderabad and Bengaluru.



Ongoing Projects: Creditable CSR goals

Parexel is continuously looking for ways to serve the community; for the greater good. Some of their ongoing CSR projects include support to Hearing impaired Children with Ashrya Akrti, Cancer Care Support project with Humanist, Medical Equipment Support to primary healthcare centres, the Women's Livelihood program, Telemedicine setup and Medical Equipment support to PGIMER Chandigarh. These initiatives will benefit thousands of patients and people from vulnerable communities.



Supply that's Safe, Secure & Sustainable

At Pharmapoint Group, the principles of Corporate Social Responsibility (CSR), Sustainability, and Environmental, Social, and Governance (ESG) are integral to their operations, guiding them in fostering ethical business practices that benefit society and safeguard the environment. These values are especially critical in the management of specialty life-saving drugs, where their actions directly influence lives and support patient communities.

Below is an overview of Pharmapoint's key initiatives and accomplishments in 2024:

Corporate Social Responsibility (CSR)

The company's CSR efforts are directed towards addressing societal, environmental, and ethical challenges through the following measures:

Access to Life-Saving Medications, Anytime-Anywhere

- **Reliable Distribution:** They ensure the seamless distribution of time- and temperature-sensitive life-saving drugs, maintaining stringent storage conditions to reach underserved and economically disadvantaged regions across the country.
- **Strategic Partnerships:** Collaborate with principal companies and patient assistance programs (PAP) to enhance access to essential medications, ensuring equity in healthcare delivery.

Education and Awareness

- **Health Education Campaigns:** Facilitate awareness about disease prevention, treatment modalities, and the significance of adherence to prescribed therapies.
- **Collaborative Workshops:** Partner with healthcare institutions and community organizations to disseminate educational materials and conduct workshops on proper drug usage and healthcare best practices. (Example: Continuous Medical Education (CME) programs on oncology therapies in partnership with a prominent hospital group.)

Ethical Sourcing and Fair Trade

- **Transparent Supply Chain:** Uphold human rights, fair labor practices, and supply chain transparency in the distribution of life-saving drugs.
- **Diversity and Inclusion:** Foster an inclusive work environment by promoting equitable hiring practices within the organization and among their partners.

Sustainability

At Pharmapoint Group, sustainability transcends environmental concerns to include responsible business practices that ensure long-term economic and social value creation.



Eco-Friendly Packaging and Distribution

- **Sustainable Packaging:** Employ recyclable and biodegradable materials to minimize waste generation.
- **Optimized Logistics:** Reduce carbon emissions by optimizing supply chains and employing electric vehicles for deliveries.



Waste Management

- **Take-Back Program:** Implement a structured program for the retrieval and safe disposal of unused shipping materials, thereby preventing environmental contamination.

Energy Efficiency

- **Renewable Energy Adoption:** Transition to renewable energy sources for operational facilities such as warehouses and offices.
- **Energy-Saving Technologies:** Integrate advanced technologies, including LED lighting and energy-efficient appliances, into daily operations to enhance energy efficiency.



Key Activities and Initiatives

Fostering Innovation in Healthcare

- **Ethical Sourcing:** Adhere to Good Distribution Practices (GDP) and prioritize stringent Standard Operating Procedures (SOPs). Ensure that sourcing practices for shipping materials are environmentally responsible and socially sustainable.
- **Advancing HealthTech:** Leverage digital health solutions such as their "SMART SUVIDHA" app to empower patients and healthcare providers, improving the accessibility and quality of healthcare services.




Stakeholder Engagement

- **Collaborative Dialogue:** Maintain regular engagement with stakeholders, including patients, healthcare providers, and regulatory bodies, to align their CSR, sustainability, and ESG initiatives with their expectations and needs.

Enhancing Medication Safety and Quality Control

- **Stringent Quality Standards:** Ensure that medications are stored, handled, and transported in compliance with rigorous guidelines to maintain their integrity and efficacy.
- **Counterfeit Drug Prevention:** Partner with principal companies and regulatory authorities to implement track-and-trace mechanisms, thereby mitigating the risk of counterfeit medications.
- **Supply Chain Resilience:** Streamline supply chain operations to prevent stockouts of essential medications, ensuring continuity of care during crises such as the COVID-19 pandemic.



Leveraging Technology for Enhanced Healthcare Delivery



- **Advanced Tracking Systems:** Utilize cutting-edge tracking and monitoring systems to ensure timely and accurate delivery of medications under optimal conditions.
- **Data-Driven Insights:** Employ predictive analytics to forecast medication demand, mitigating shortages and ensuring a consistent supply of critical drugs to sustain patient care.

By embedding CSR, Sustainability, and ESG principles into their operations, Pharmapoint Group not only delivers societal value but also strengthens its reputation as a trusted and responsible leader in the healthcare industry. Through these efforts, they reaffirm their commitment to improving lives, fostering innovation, and promoting sustainable development.

OPPI ORDINARY MEMBERS



OPPI AFFILIATE MEMBERS



About OPPI

The Organisation of Pharmaceutical Producers of India (OPPI) established in 1965, represents the research-based global pharmaceutical companies in India. OPPI has been an integral part of the healthcare journey of the country. We remain committed to supporting the nation's healthcare objectives, putting patients at the core of all decision making and collaborating with all stakeholders to find sustainable solutions to realize the collective vision of Health for All.

Our member companies have been serving the country's healthcare ecosystem since pre-independence and continue to remain committed to patient safety and providing quality care in the future as well. As an association, our advocacy decisions, patient commitment and work are always keeping the country first and we embody the spirit of working for 'Bharat Ke Liye'; driven with innovation to find solutions for unmet medical needs, collaboration with government stakeholders, and co-creation with partners coming together to address the nation's healthcare challenges. We are committed to the Hon'ble Prime Minister Shri Narendra Modi-ji's clarion call of 'Jai Vigyan and Jai Anusandhan'.

About Bharat Ke Liye

Bharat Ke Liye captures the essence of OPPI's commitment towards India, one that's backed by innovative solutions with a mission to improve the country's healthcare infrastructure. Along with our member companies, we have been a strong partner to the nation since pre-independence. With a strong Indian ethos and a deep understanding of the country's complex fabric, we have been investing in India to build a healthier and stronger country.

As we move towards India@100, we will continue to partner the with Government to advance its vision of Healthcare for All, investing in building India's capability to solve for health challenges of its people & the world at large. It's important now more than ever before to CONVERGE, COLLABORATE, and CO-CREATE with the Government and other stakeholders in India.

We are #BharatKeliye

We were there

Since pre-independence, we've partnered with India to eradicate many diseases, address many epidemics, and solve health problems; together.

We are there

We've been collaborating for critical support during the pandemic, co-creating with the government to strengthen our healthcare ecosystem, converging our knowledge, and leveraging technology to innovate for unmet medical needs, all in an effort to improve the quality of care & access to healthcare.

We will be there

As we work towards India@100, we pledge to keep investing in the future of the nation, pushing boundaries of innovation, research, and development, to make every Indian healthy, prosperous, and resilient.

Partnering India on its mission to progress, amplifying our Hon'ble PM Shri Narendra Modiji's clarion call of **Jai Vigyan, Jai Anusandhan!**

Connect with us on:



@OPPIIndia



OPPI India



Organisation of Pharmaceutical
Producers of India (OPPI)



communications@indiaoppi.com



www.indiaoppi.com

Editor - **Asawari Sathaye**, *Director Communications and Patient Advocacy, OPPI*
Content Coordinator - **Clara Rodricks**, *Executive Assistant, OPPI*

We gratefully acknowledge the support received from our members companies.

The contents of Year End Dossier are the copyright property of Organisation of Pharmaceutical Producers of India. Content may not be reproduced in any form without prior written permission.

भारत के लिए



OPPI



भारत के लिए

Organisation of Pharmaceutical Producers of India

Registered Office: 1620, C Wing, One BKC, Bandra Kurla Complex,
Bandra East, Mumbai-400051, India.

Delhi Office: Avanta Business Centre, Cabin No. 3.08, 3rd Floor, Ambadeep Building,
K. G. Marg, Connaught Place, New Delhi - 110001, India.

Copyright©2025 OPPI